Vol.:(0123456789) Vol.:(0123456789) vol.:(0123456789) V Vo Vol Vol. BLOCKSTART PAGESTART NEWFONT HIGHERFONT 0 0 INITCAP CONTAINSDIGITS 0 0 0 0 1 0 0 0 0 0 .:() 4 10 0 1 0 0 0
Dermatol Ther dermatol D De Der Derm BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 0 0 ()():- 6 10 0 1 1 1 1
https://doi.org/10.1007/s13555-024-01231-y https://doi.org/10.1007/s13555-024-01231-y https://doi.org/10.1007/s13555-024-01231-y h ht htt http BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS CONTAINSDIGITS 0 0 0 0 1 0 0 1 0 0 ://././--- 10 9 0 1 0 0 1
ORIGINAL RESEARCH original O OR ORI ORIG BLOCKSTART PAGEIN SAMEFONT HIGHERFONT 0 0 ALLCAP NODIGIT 0 0 1 0 0 0 0 0 0 0 no 0 10 0 1 0 0 1
Dupilumab Reduces dupilumab D Du Dup Dupi BLOCKSTART PAGEIN NEWFONT HIGHERFONT 1 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 0 0 ,, 2 9 0 0 0 0 1
and Hives and a an and and BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 0 no 0 10 0 0 0 0 1
Urticaria Regardless urticaria U Ur Urt Urti BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 0 0 no 0 8 0 0 0 0 1
Immunoglobulin E immunoglobulin I Im Imm Immu BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 1 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 0 0 no 0 5 0 0 0 0 1
Marcus Maurer marcus M Ma Mar Marc BLOCKSTART PAGEIN NEWFONT LOWERFONT 0 0 INITCAP NODIGIT 0 1 0 0 0 0 0 0 0 0 •.•.•-• 7 10 0 0 0 0 1
Elizabeth Laws elizabeth E El Eli Eliz BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 1 0 0 0 0 0 0 0 1 •••• 4 10 0 0 0 0 1
Received: May received: R Re Rec Rece BLOCKSTART PAGEIN SAMEFONT LOWERFONT 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 0 1 :,/:,/:, 8 10 0 0 0 0 1
© The © © © © © BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 1 0 0 0 0 0 0 0 0 1 () 2 2 0 0 0 0 1
ABSTRACT ABSTRACT abstract A AB ABS ABST BLOCKSTART PAGEIN NEWFONT HIGHERFONT 0 0 ALLCAP NODIGIT 0 0 1 0 0 0 0 0 0 1 no 0 10 0 0 0 0 1
Introduction: In introduction: I In Int Intr BLOCKSTART PAGEIN NEWFONT LOWERFONT 1 1 INITCAP NODIGIT 0 0 1 0 0 0 0 0 0 1 : 1 9 0 0 0 0 1
(CSU), interleukin (csu), ( (C (CS (CSU BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 1 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 0 1 (),()-- 7 9 0 0 0 0 1
mast cell mast m ma mas mast BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 1 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 0 1 - 1 9 0 0 0 0 1
expression, or expression, e ex exp expr BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 1 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 1 ,- 2 9 0 0 0 0 1
noglobulin E noglobulin n no nog nogl BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 1 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 0 1 ().- 4 8 0 0 0 0 1
nificantly improved nificantly n ni nif nifi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 1 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 0 1 no 0 8 0 0 0 0 1
in the in i in in in BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 1 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 0 1 ,,- 3 9 0 0 0 0 1
LIBERTY-CSU CUPID liberty-csu L LI LIB LIBE BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 1 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 0 1 -. 2 8 0 0 0 0 1
explores the explores e ex exp expl BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 1 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 1 no 0 9 0 0 0 0 1
and symptoms and a an and and BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 1 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 1 no 0 9 0 0 0 0 1
from LIBERTY-CSU from f fr fro from BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 1 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 1 - 1 8 0 0 0 0 1
total IgE total t to tot tota BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 1 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 1 /. 2 9 0 0 0 0 1
Methods: Patients methods: M Me Met Meth BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 1 INITCAP NODIGIT 0 0 1 0 0 0 0 0 0 1 :-- 3 7 0 0 0 0 1
refractory CSU refractory r re ref refr BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 1 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 0 1 () 2 9 0 0 0 0 1
placebo (n placebo p pl pla plac BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 1 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 1 (). 3 9 0 0 0 0 1
were change were w we wer were BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 1 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 1 no 0 9 0 0 0 0 1
serum total serum s se ser seru BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 1 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 1 , 1 10 0 0 0 0 1
days (ISS7), days d da day days BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 1 1 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 1 (), 3 9 0 0 0 0 1
Prior Presentation: prior P Pr Pri Prio BLOCKSTART PAGEIN NEWFONT LOWERFONT 1 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 0 4 :(),,,. 7 10 0 0 0 0 1
Dupilumab significantly dupilumab D Du Dup Dupi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 0 4 no 0 9 0 0 0 0 1
chronic spontaneous chronic c ch chr chro BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 4 : 1 10 0 0 0 0 1
(LIBERTY-CSU CUPID (liberty-csu ( (L (LI (LIB BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 0 4 (-).() 6 9 0 0 0 0 1
European Academy european E Eu Eur Euro BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 0 4 no 0 8 0 0 0 0 1
meeting; Prague, meeting; m me mee meet BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 4 ;,;-; 5 9 0 0 0 0 1
001593. Abstract 001593. 0 00 001 0015 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 ALLCAP CONTAINSDIGITS 0 0 0 0 1 0 0 0 0 4 .:., 4 9 0 0 0 0 1
2023. 78; 2023. 2 20 202 2023 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 ALLCAP CONTAINSDIGITS 0 0 0 0 1 0 0 0 0 4 .;-.(),,,. 10 9 0 0 0 0 1
Dupilumab significantly dupilumab D Du Dup Dupi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 0 4 no 0 8 0 0 0 0 1
patients with patients p pa pat pati BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 4 no 0 9 0 0 0 0 1
of baseline of o of of of BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 6 :(- 3 10 0 0 0 0 1
CSU CUPID csu C CS CSU CSU BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 0 6 ).() 4 8 0 0 0 0 1
Congress of congress C Co Con Cong BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 0 6 no 0 7 0 0 0 0 1
and Venereology and a an and and BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 6 ,;-; 4 8 0 0 0 0 1
abstract 2907. abstract a ab abs abst BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 6 .(),, 5 8 0 0 0 0 1
A, et a, A A, A, A, BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 1 0 0 0 0 0 0 6 ,. 2 9 0 0 0 0 1
crónica espontánea crónica c cr cró crón BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 0 6 no 0 9 0 0 0 0 1
largo del largo l la lar larg BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 0 6 :-. 3 8 0 0 0 0 1
(Poster) presented (poster) ( (P (Po (Pos BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 0 6 () 2 8 0 0 0 0 1
Sociedad Española sociedad S So Soc Soci BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 0 6 no 0 9 0 0 0 0 1
2023 in 2023 2 20 202 2023 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 1 0 0 0 0 6 , 1 8 0 0 0 0 1
Compostela, Spain; compostela, C Co Com Comp BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 0 6 ,;-.(), 7 8 0 0 0 0 1
Casale T, casale C Ca Cas Casa BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 0 6 ,,. 3 9 0 0 0 0 1
with chronic with w wi wit with BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 6 :- 2 9 0 0 0 0 1
CSU CUPID csu C CS CSU CSU BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 0 6 .() 3 8 0 0 0 0 1
the 2022 the t th the the BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 6 ,, 2 8 0 0 0 0 1
and Immunology and a an and and BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 6 ,, 2 8 0 0 0 0 1
USA; 10-14 usa; U US USA USA; BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 0 6 ;-.: 4 8 0 0 0 0 1
Allergy, Asthma allergy, A Al All Alle BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 0 6 ,.;():.() 9 8 0 0 0 0 1
Maurer M, maurer M Ma Mau Maur BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 1 0 0 0 0 0 0 0 6 ,,,. 4 9 0 0 0 0 1
in patients in i in in in BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 0 6 no 0 8 0 0 0 0 1
level and level l le lev leve BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 6 :-. 3 8 0 0 0 0 1
(Oral Presentation) (oral ( (O (Or (Ora BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 0 6 () 2 8 0 0 0 0 1
and Clinical and a an and and BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 6 , 1 8 0 0 0 0 1
Germany; 9-11 germany; G Ge Ger Germ BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 0 6 ;-.: 4 8 0 0 0 0 1
(OAS). Allergy, (oas). ( (O (OA (OAS BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 0 6 ().,.:-. 8 8 0 0 0 0 1
of LIBERTY-CSU of o of of of BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 6 - 1 8 0 0 0 0 1
previously. (6) previously. p pr pre prev BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 6 .(),,,. 7 8 0 0 0 0 1
Dupilumab in dupilumab D Du Dup Dupi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 0 6 no 0 7 0 0 0 0 1
urticaria (LIBERTY-CSU urticaria u ur urt urti BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 0 6 (-):,- 6 8 0 0 0 0 1
blind, placebo-controlled, blind, b bl bli blin BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 6 ,-,. 4 9 0 0 0 0 1
Immunol. 2024;S0091-6749(24)00196-9. immunol. I Im Imm Immu BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 0 6 .;-()-.://./ 12 9 0 0 0 0 1
10. 1016/j. 10. 1 10 10. 10. BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 0 6 ./..... 7 5 0 0 0 0 1
Supplementary Information supplementary S Su Sup Supp BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 1 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 0 11 no 0 9 0 1 0 0 1
contains supplementary contains c co con cont BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 11 no 0 9 0 1 0 0 1
https:// doi. https:// h ht htt http BLOCKEND PAGEEND SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 1 0 11 ://././---. 11 10 0 1 0 0 1
2428 2428 2428 2 24 242 2428 BLOCKSTART PAGESTART NEWFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 1 0 0 0 0 0 no 0 10 0 1 0 0 1
Dermatol Ther dermatol D De Der Derm BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 0 0 ()():- 6 10 0 1 1 0 1
(UAS7), and (uas7), ( (U (UA (UAS BLOCKSTART PAGEIN NEWFONT HIGHERFONT 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 0 0 (), 3 8 0 0 0 0 1
(HSS7) in (hss7) ( (H (HS (HSS BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 0 0 ()-- 4 9 0 0 0 0 1
with serum with w wi wit with BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 0 / 1 8 0 0 0 0 1
mL at ml m mL mL mL BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 0 0 . 1 3 0 0 0 0 1
Results: Dupilumab results: R Re Res Resu BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 0 0 : 1 8 0 0 0 0 1
reduced median reduced r re red redu BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 0 () 2 9 0 0 0 0 1
at week at a at at at BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 0 [:-.(-.;-.); 12 9 0 0 0 0 1
placebo: -6.3% placebo: p pl pla plac BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 0 :-.(-.;.)] 10 8 0 0 0 0 1
[dupilumab: -48.2% [dupilumab: [ [d [du [dup BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 0 0 [:-.(-.;-.);: 13 8 0 0 0 0 1
-6.3% (-34.5; -6.3% - -6 -6. -6.3 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 0 0 -.(-.;.)].- 11 9 0 0 0 0 1
ative to ative a at ati ativ BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 0 0 - 1 8 0 0 0 0 1
treated patients treated t tr tre trea BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 0 . 1 10 0 0 0 0 1
Dupilumab treatment dupilumab D Du Dup Dupi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 0 0 ,, 2 8 0 0 0 0 1
HSS7 over hss7 H HS HSS HSS7 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 0 0 ,- 2 9 0 0 0 0 1
line serum line l li lin line BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 0 (. 2 10 0 0 0 0 1
treatment by treatment t tr tre trea BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 0 ), 2 9 0 0 0 0 1
correlations (r correlations c co cor corr BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 0 (.) 3 9 0 0 0 0 1
changes and changes c ch cha chan BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 0 0 ,,. 3 8 0 0 0 0 1
Conclusions: Dupilumab conclusions: C Co Con Conc BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 0 0 : 1 7 0 0 0 0 1
improved CSU improved i im imp impr BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 0 no 0 8 0 0 0 0 1
serum IgE, serum s se ser seru BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 0 ,. 2 9 0 0 0 0 1
the current the t th the the BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 0 , 1 8 0 0 0 0 1
no predictive no n no no no BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 0 no 0 8 0 0 0 0 1
response biomarker response r re res resp BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 4 . 1 8 0 0 0 0 1
IgE, a ige, I Ig IgE IgE, BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 1 4 , 1 9 0 0 0 0 1
histamine release, histamine h hi his hist BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 1 4 , 1 9 0 0 0 0 1
the effectiveness the t th the the BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 4 no 0 9 0 0 0 0 1
signs and signs s si sig sign BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 4 . 1 3 0 0 0 0 1
Trial Registration: trial T Tr Tri Tria BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 1 1 0 0 0 0 0 1 4 :.: 3 10 0 0 0 0 1
NCT04180488. NCT04180488. nct04180488. N NC NCT NCT0 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 1 0 0 0 1 4 . 1 2 0 0 0 0 1
Keywords: Biomarker; keywords: K Ke Key Keyw BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 1 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 1 4 :; 2 9 0 0 0 0 1
urticaria; CSU; urticaria; u ur urt urti BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 1 4 ;;;; 4 10 0 0 0 0 1
IgE; Omalizumab-naïve; ige; I Ig IgE IgE; BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 1 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 1 4 ;-; 3 9 0 0 0 0 1
Key Summary key K Ke Key Key BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 1 0 INITCAP NODIGIT 0 1 1 0 0 0 0 0 1 5 no 0 10 0 0 0 0 1
Why carry why W Wh Why Why BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 1 INITCAP NODIGIT 0 0 1 0 0 0 0 0 1 5 ? 1 10 0 0 0 0 1
Key drivers key K Ke Key Key BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 1 1 0 0 0 0 0 1 5 no 0 10 0 0 0 0 1
(CSU) pathophysiology (csu) ( (C (CS (CSU BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 1 5 (), 3 9 0 0 0 0 1
eosinophils, and eosinophils, e eo eos eosi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 1 5 , 1 8 0 0 0 0 1
in part in i in in in BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 1 5 , 1 9 0 0 0 0 1
such as such s su suc such BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 5 ()--, 5 9 0 0 0 0 1
increased immunoglobulin increased i in inc incr BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 5 ()- 3 8 0 0 0 0 1
tion. Dupilumab tion. t ti tio tion BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 1 5 . 1 9 0 0 0 0 1
improvements in improvements i im imp impr BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 5 no 0 8 0 0 0 0 1
of CSU of o of of of BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 5 ,-, 3 9 0 0 0 0 1
double-blind phase double-blind d do dou doub BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 5 -(- 3 8 0 0 0 0 1
CUPID Study cupid C CU CUP CUPI BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 1 5 ). 2 3 0 0 0 0 1
This analysis this T Th Thi This BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 1 6 no 0 8 0 0 0 0 1
dupilumab in dupilumab d du dup dupi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 1 6 no 0 10 0 0 0 0 1
serum total serum s se ser seru BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 6 , 1 9 0 0 0 0 1
serum total serum s se ser seru BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 6 , 1 9 0 0 0 0 1
to determine to t to to to BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 6 no 0 10 0 0 0 0 1
predictor of predictor p pr pre pred BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 1 6 . 1 7 0 0 0 0 1
What was what W Wh Wha What BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 1 INITCAP NODIGIT 0 0 1 0 0 0 0 0 1 7 ? 1 10 0 0 0 0 1
Dupilumab is dupilumab D Du Dup Dupi BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 1 7 no 0 8 0 0 0 0 1
H1-antihistamine (H1-AH)-resistant, h1-antihistamine H H1 H1- H1-a BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 1 7 -(-)-,- 7 8 0 0 0 0 1
izumab-naïve patients izumab-naïve i iz izu izum BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 1 7 -,- 3 8 0 0 0 0 1
less of less l le les less BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 7 . 1 10 0 0 0 0 1
Dupilumab treatment dupilumab D Du Dup Dupi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 1 7 no 0 8 0 0 0 0 1
and symptoms and a an and and BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 7 , 1 9 0 0 0 0 1
but these but b bu but but BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 7 . 1 8 0 0 0 0 1
These results these T Th The Thes BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 1 8 no 0 10 0 0 0 0 1
dupilumab in dupilumab d du dup dupi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 1 8 - 1 9 0 0 0 0 1
ulation and ulation u ul ula ulat BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 1 8 - 1 9 0 0 0 0 1
ways involving ways w wa way ways BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 8 -/-. 4 8 0 0 0 0 1
M. Maurer m. M M. M. M. BLOCKSTART PAGEIN SAMEFONT LOWERFONT 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 1 9 .(*) 4 2 0 0 0 0 1
Institute of institute I In Ins Inst BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 1 9 ,- 2 10 0 0 0 0 1
Berlin, Corporate berlin, B Be Ber Berl BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 1 9 , 1 8 0 0 0 0 1
of Berlin of o of of of BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 9 -, 2 8 0 0 0 0 1
Hindenburgdamm 27, hindenburgdamm H Hi Hin Hind BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 1 9 ,, 2 7 0 0 0 0 1
e-mail: marcus.maurer@charite.de e-mail: e e- e-m e-ma BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 1 9 -:.@. 5 6 0 0 0 0 1
M. Maurer m. M M. M. M. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 1 9 . 1 2 0 0 0 0 1
Fraunhofer Institute fraunhofer F Fr Fra Frau BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 1 9 no 0 10 0 0 0 0 1
and Pharmacology and a an and and BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 9 , 1 7 0 0 0 0 1
and Allergology, and a an and and BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 9 ,, 2 6 0 0 0 0 1
T. B. t. T T. T. T. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 1 10 .. 2 2 0 0 0 0 1
Division of division D Di Div Divi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 1 10 , 1 10 0 0 0 0 1
of South of o of of of BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 10 ,,, 3 7 0 0 0 0 1
S. S. s. S S. S. S. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 1 10 .. 2 2 0 0 0 0 1
Johns Hopkins johns J Jo Joh John BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 1 0 0 0 0 0 0 1 10 , 1 10 0 0 0 0 1
Baltimore, MD, baltimore, B Ba Bal Balt BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 1 10 ,, 2 4 0 0 0 0 1
M. Ben-Shoshan m. M M. M. M. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 1 10 .- 2 2 0 0 0 0 1
Division of division D Di Div Divi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 1 10 //, 3 8 0 0 0 0 1
Department of department D De Dep Depa BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 1 10 , 1 10 0 0 0 0 1
Centre, Montreal, centre, C Ce Cen Cent BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 1 10 ,,, 3 5 0 0 0 0 1
E. Laws e. E E. E. E. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 1 11 .•. 3 6 0 0 0 0 1
Sanofi, Bridgewater, sanofi, S Sa San Sano BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 1 11 ,,, 3 10 0 0 0 0 1
J. Maloney j. J J. J. J. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 1 11 .•. 3 4 0 0 0 0 1
Regeneron Pharmaceuticals regeneron R Re Reg Rege BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 1 11 .,,, 4 10 0 0 0 0 1
USA USA usa U US USA USA BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 1 11 no 0 0 0 0 0 0 1
M. Makhija m. M M. M. M. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 1 11 . 1 4 0 1 0 0 1
Sanofi, Cambridge, sanofi, S Sa San Sano BLOCKEND PAGEEND SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 1 11 ,,, 3 10 0 1 0 0 1
2429 2429 2429 2 24 242 2429 BLOCKSTART PAGESTART NEWFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 1 0 0 0 1 0 no 0 1 0 1 0 0 1
Dermatol Ther dermatol D De Der Derm BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 1 0 ()():- 6 10 0 1 1 0 1
INTRODUCTION INTRODUCTION introduction I IN INT INTR BLOCKSTART PAGEIN NEWFONT HIGHERFONT 0 0 ALLCAP NODIGIT 0 0 1 0 0 0 0 0 1 0 no 0 10 0 1 0 0 1
Chronic spontaneous chronic C Ch Chr Chro BLOCKSTART PAGEIN NEWFONT LOWERFONT 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 1 0 () 2 9 0 0 0 0 1
inflammatory skin inflammatory i in inf infl BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 1 0 no 0 9 0 0 0 0 1
recurrence of recurrence r re rec recu BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 0 / 1 8 0 0 0 0 1
associated itch, associated a as ass asso BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 0 ,,- 3 9 0 0 0 0 1
nificantly impact nificantly n ni nif nifi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 1 0 [-]. 4 8 0 0 0 0 1
Type 2 type T Ty Typ Type BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 1 0 - 1 8 0 0 0 0 1
leukin (IL)-4 leukin l le leu leuk BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 1 0 ()--,, 6 9 0 0 0 0 1
a role a a a a a BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 1 0 1 0 0 0 0 0 1 0 no 0 9 0 0 0 0 1
indirect activation indirect i in ind indi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 0 ,, 2 10 0 0 0 0 1
eosinophils, as eosinophils, e eo eos eosi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 1 0 ,- 2 9 0 0 0 0 1
into the into i in int into BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 0 - 1 9 0 0 0 0 1
moting itch moting m mo mot moti BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 1 0 [,].--- 7 9 0 0 0 0 1
late B-cell late l la lat late BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 0 -- 2 9 0 0 0 0 1
ing to ing i in ing ing BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 0 0 0 0 0 0 1 0 (), 3 9 0 0 0 0 1
increased IgE increased i in inc incr BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 0 []. 3 9 0 0 0 0 1
the activation the t th the the BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 0 , 1 9 0 0 0 0 1
which leads which w wh whi whic BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 0 no 0 8 0 0 0 0 1
itch in itch i it itc itch BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 0 ., 2 9 0 0 0 0 1
the expression the t th the the BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 0 -- 2 9 0 0 0 0 1
tor FcεR1 tor t to tor tor BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 1 0 , 1 9 0 0 0 0 1
in mast in i in in in BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 1 0 []. 3 9 0 0 0 0 1
In a in I In In In BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 1 1 0 0 0 0 0 1 0 , 1 9 0 0 0 0 1
of 926 of o of of of BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 0 no 0 9 0 0 0 0 1
levels above levels l le lev leve BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 0 /[].- 5 9 0 0 0 0 1
analysis including analysis a an ana anal BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 0 no 0 10 0 0 0 0 1
866 patients 866 8 86 866 866 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 1 0 , 1 9 0 0 0 0 1
were below were w we wer were BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 0 / 1 9 0 0 0 0 1
response to response r re res resp BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 0 []. 3 5 0 0 0 0 1
Current therapies current C Cu Cur Curr BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 1 0 ,-- 3 9 0 0 0 0 1
histamines (H1-AH) histamines h hi his hist BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 1 0 (-)(-), 7 9 0 0 0 0 1
do not do d do do do BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 0 no 0 8 0 0 0 0 1
patients, which patients, p pa pat pati BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 0 , 1 9 0 0 0 0 1
for alternative for f fo for for BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 0 [,,]. 5 9 0 0 0 0 1
is a is i is is is BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 0 -- 2 9 0 0 0 0 1
clonal antibody clonal c cl clo clon BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 1 0 [,] 3 9 0 0 0 0 1
receptor component receptor r re rec rece BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 0 (-)--, 6 9 0 0 0 0 1
and thus and a an and and BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 0 - 1 10 0 0 0 0 1
ers of ers e er ers ers BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 1 0 [,].- 5 9 0 0 0 0 1
CSU CUPID csu C CS CSU CSU BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 1 0 () 2 7 0 0 0 0 1
randomized, placebo-controlled, randomized, r ra ran rand BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 1 0 ,-,- 4 9 0 0 0 0 1
phase 3 phase p ph pha phas BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 0 no 0 9 0 0 0 0 1
in omalizumab-naïve in i in in in BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 1 0 - 1 8 0 0 0 0 1
remained symptomatic remained r re rem rema BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 0 -. 2 8 0 0 0 0 1
Dupilumab demonstrated dupilumab D Du Dup Dupi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 1 0 - 1 8 0 0 0 0 1
ments in ments m me men ment BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 1 0 , 1 8 0 0 0 0 1
the overall the t th the the BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 0 no 0 9 0 0 0 0 1
the known the t th the the BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 0 []. 3 8 0 0 0 0 1
Previous studies previous P Pr Pre Prev BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 2 6 no 0 8 0 0 0 0 1
between reduction between b be bet betw BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 6 no 0 8 0 0 0 0 1
improvement in improvement i im imp impr BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 6 no 0 9 0 0 0 0 1
with type with w wi wit with BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 6 no 0 9 0 0 0 0 1
dupilumab [17-20]. dupilumab d du dup dupi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 2 6 [-]. 4 9 0 0 0 0 1
LIBERTY-CSU CUPID liberty-csu L LI LIB LIBE BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 2 6 -, 2 8 0 0 0 0 1
that dupilumab that t th tha that BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 6 no 0 9 0 0 0 0 1
IgE levels ige I Ig IgE IgE BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 2 6 .-/- 4 9 0 0 0 0 1
in CSU in i in in in BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 2 6 no 0 9 0 0 0 0 1
activation, immune-cell activation, a ac act acti BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 6 ,-,- 4 9 0 0 0 0 1
ronal sensitization ronal r ro ron rona BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 2 6 [,-], 5 9 0 0 0 0 1
that the that t th tha that BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 6 - 1 9 0 0 0 0 1
pendent of pendent p pe pen pend BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 2 6 .- 2 10 0 0 0 0 1
ysis evaluated ysis y ys ysi ysis BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 2 6 no 0 10 0 0 0 0 1
on CSU on o on on on BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 6 no 0 9 0 0 0 0 1
levels in levels l le lev leve BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 6 - 1 9 0 0 0 0 1
stratified by stratified s st str stra BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 6 . 1 9 0 0 0 0 1
METHODS METHODS methods M ME MET METH BLOCKSTART PAGEIN NEWFONT HIGHERFONT 0 0 ALLCAP NODIGIT 0 0 1 0 0 0 0 0 2 9 no 0 10 0 0 0 0 1
Study Design study S St Stu Stud BLOCKSTART PAGEIN NEWFONT LOWERFONT 1 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 2 9 no 0 10 0 0 0 0 1
LIBERTY-CSU CUPID liberty-csu L LI LIB LIBE BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 2 9 --, 3 8 0 0 0 0 1
multicenter, randomized, multicenter, m mu mul mult BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 2 9 ,,-, 4 9 0 0 0 0 1
double-blind, phase double-blind, d do dou doub BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 9 -, 2 8 0 0 0 0 1
patients with patients p pa pat pati BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 9 . 1 8 0 0 0 0 1
study was study s st stu stud BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 9 no 0 8 0 0 0 0 1
ethical standards ethical e et eth ethi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 9 , 1 9 0 0 0 0 1
the Declaration the t th the the BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 9 , 1 9 0 0 0 0 1
Conference on conference C Co Con Conf BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 2 9 no 0 8 0 0 0 0 1
Practice guidelines, practice P Pr Pra Prac BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 2 9 , 1 9 0 0 0 0 1
requirements. All requirements. r re req requ BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 9 ./ 2 9 0 0 0 0 1
guardians provided guardians g gu gua guar BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 9 no 0 8 0 0 0 0 1
before participating before b be bef befo BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 9 .- 2 10 0 0 0 0 1
atric patients, atric a at atr atri BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 2 9 , 1 9 0 0 0 0 1
to the to t to to to BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 9 [ 1 9 0 0 0 0 1
Board (IRB)/Independent board B Bo Boa Boar BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 2 9 ()/]- 5 8 0 0 0 0 1
approved standard approved a ap app appr BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 9 no 0 10 0 0 0 0 1
at each at a at at at BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 9 . 1 6 0 0 0 0 1
Patients and patients P Pa Pat Pati BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 1 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 2 11 no 0 10 0 0 0 0 1
Detailed eligibility detailed D De Det Deta BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 2 11 - 1 8 0 0 0 0 1
CUPID Study cupid C CU CUP CUPI BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 2 11 no 0 8 0 0 0 0 1
et al. et e et et et BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 2 11 .[].,- 6 10 0 0 0 0 1
ERTY-CSU CUPID erty-csu E ER ERT ERTY BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 2 11 -, 2 8 0 0 0 0 1
had had had h ha had had BLOCKEND PAGEEND SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 11 no 0 8 0 0 0 0 1
2430 2430 2430 2 24 243 2430 BLOCKSTART PAGESTART NEWFONT LOWERFONT 0 0 NOCAPS ALLDIGIT 0 0 0 0 1 0 0 0 2 0 no 0 10 0 1 0 0 1
Dermatol Ther dermatol D De Der Derm BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 2 0 ()():- 6 10 0 1 1 0 1
months prior months m mo mon mont BLOCKSTART PAGEIN NEWFONT HIGHERFONT 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 0 , 1 10 0 0 0 0 1
itch and itch i it itc itch BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 0 no 0 10 0 0 0 0 1
H1-AH use, h1-ah H H1 H1- H1-A BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 2 0 -, 2 9 0 0 0 0 1
days (UAS7) days d da day days BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 0 () 2 9 0 0 0 0 1
days (ISS7) days d da day days BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 0 (),, 4 9 0 0 0 0 1
received background received r re rec rece BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 0 no 0 9 0 0 0 0 1
the licensed the t th the the BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 0 -. 2 5 0 0 0 0 1
Study participants study S St Stu Stud BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 2 0 : 1 8 0 0 0 0 1
receive either receive r re rec rece BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 0 . 1 9 0 0 0 0 1
Adults and adults A Ad Adu Adul BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 2 0 no 0 9 0 0 0 0 1
mg loading mg m mg mg mg BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 2 0 no 0 8 0 0 0 0 1
weeks, adolescents weeks, w we wee week BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 0 , 1 9 0 0 0 0 1
received a received r re rec rece BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 0 no 0 9 0 0 0 0 1
mg every mg m mg mg mg BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 2 0 , 1 9 0 0 0 0 1
kg received kg k kg kg kg BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 2 0 no 0 9 0 0 0 0 1
300 mg 300 3 30 300 300 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 2 0 . 1 4 0 0 0 0 1
Endpoints Endpoints endpoints E En End Endp BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 1 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 2 2 no 0 10 0 0 0 0 1
The primary the T Th The The BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 2 2 - 1 8 0 0 0 0 1
A have a A A A A BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 1 0 1 0 0 0 0 0 2 2 []. 3 9 0 0 0 0 1
subgroup analysis, subgroup s su sub subg BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 2 , 1 8 0 0 0 0 1
change in change c ch cha chan BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 2 no 0 10 0 0 0 0 1
week 12 week w we wee week BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 2 ,,, 3 9 0 0 0 0 1
and Hives and a an and and BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 2 () 2 9 0 0 0 0 1
baseline at baseline b ba bas base BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 2 2 no 0 9 0 0 0 0 1
serum total serum s se ser seru BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 2 / 1 9 0 0 0 0 1
baseline. baseline. baseline. b ba bas base BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 2 2 . 1 2 0 0 0 0 1
Safety endpoints safety S Sa Saf Safe BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 2 2 no 0 8 0 0 0 0 1
patients with patients p pa pat pati BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 2 - 1 9 0 0 0 0 1
adverse event adverse a ad adv adve BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 2 (), 3 9 0 0 0 0 1
with any with w wi wit with BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 2 ,, 2 9 0 0 0 0 1
patients with patients p pa pat pati BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 2 - 1 9 0 0 0 0 1
ation, and ation, a at ati atio BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 2 2 , 1 9 0 0 0 0 1
any treatment any a an any any BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 2 . 1 4 0 0 0 0 1
Statistical Analyses statistical S St Sta Stat BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 1 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 3 5 no 0 10 0 0 0 0 1
Unless otherwise unless U Un Unl Unle BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 3 5 ,- 2 9 0 0 0 0 1
formed in formed f fo for form BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 5 --,- 4 9 0 0 0 0 1
sisting of sisting s si sis sist BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 3 5 .- 2 9 0 0 0 0 1
ses were ses s se ses ses BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 3 5 no 0 10 0 0 0 0 1
covariance (ANCOVA) covariance c co cov cova BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 3 5 () 2 9 0 0 0 0 1
complete item complete c co com comp BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 5 no 0 9 0 0 0 0 1
baseline value, baseline b ba bas base BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 3 6 ,, 2 9 0 0 0 0 1
angioedema at angioedema a an ang angi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 3 6 ,- 2 9 0 0 0 0 1
ates. The ates. a at ate ates BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 3 6 . 1 8 0 0 0 0 1
imputed dataset imputed i im imp impu BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 3 6 no 0 9 0 0 0 0 1
forward/multiple imputation forward/multiple f fo for forw BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 3 6 / 1 8 0 0 0 0 1
the primary the t th the the BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 6 no 0 8 0 0 0 0 1
of LIBERTY-CSU of o of of of BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 6 -.- 3 8 0 0 0 0 1
son for son s so son son BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 3 6 --- 3 8 0 0 0 0 1
tion was tion t ti tio tion BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 3 6 no 0 9 0 0 0 0 1
model with model m mo mod mode BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 6 , 1 8 0 0 0 0 1
intervention group, intervention i in int inte BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 6 , 1 9 0 0 0 0 1
baseline, and baseline, b ba bas base BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 3 6 ,,- 3 9 0 0 0 0 1
group variable group g gr gro grou BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 6 --- 3 8 0 0 0 0 1
tion interaction. tion t ti tio tion BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 3 6 . 1 9 0 0 0 0 1
imputed dataset imputed i im imp impu BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 3 6 - 1 9 0 0 0 0 1
forward/multiple imputation forward/multiple f fo for forw BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 3 6 / 1 8 0 0 0 0 1
analysis of analysis a an ana anal BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 6 .- 2 9 0 0 0 0 1
lation coefficients lation l la lat lati BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 3 6 no 0 10 0 0 0 0 1
from baseline from f fr fro from BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 6 no 0 9 0 0 0 0 1
in ISS7, in i in in in BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 3 6 ,, 2 8 0 0 0 0 1
24 separately 24 2 24 24 24 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 3 6 . 1 9 0 0 0 0 1
change from change c ch cha chan BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 6 no 0 8 0 0 0 0 1
baseline at baseline b ba bas base BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 3 6 - 1 8 0 0 0 0 1
rized descriptively. rized r ri riz rize BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 3 6 . 1 10 0 0 0 0 1
calculated for calculated c ca cal calc BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 6 - 1 9 0 0 0 0 1
ticipants with ticipants t ti tic tici BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 3 6 / 1 9 0 0 0 0 1
mL or ml m mL mL mL BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 3 6 /. 2 3 0 0 0 0 1
RESULTS RESULTS results R RE RES RESU BLOCKSTART PAGEIN NEWFONT HIGHERFONT 0 0 ALLCAP NODIGIT 0 1 1 0 0 0 0 0 3 10 no 0 10 0 0 0 0 1
Patients Patients patients P Pa Pat Pati BLOCKSTART PAGEIN NEWFONT LOWERFONT 1 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 3 10 no 0 10 0 0 0 0 1
Baseline serum baseline B Ba Bas Base BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 3 10 no 0 10 0 0 0 0 1
65 placebo-treated 65 6 65 65 65 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 3 10 -- 2 8 0 0 0 0 1
patients from patients p pa pat pati BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 10 - 1 8 0 0 0 0 1
(serum IgE (serum ( (s (se (ser BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 3 10 ( 1 10 0 0 0 0 1
for 3 for f fo for for BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 10 - 1 9 0 0 0 0 1
ents). Patient ents). e en ent ents BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 3 10 ).- 3 9 0 0 0 0 1
acteristics have acteristics a ac act acte BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 3 10 []. 3 10 0 0 0 0 1
Due to due D Du Due Due BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 3 10 , 1 8 0 0 0 0 1
medians were medians m me med medi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 10 .- 2 9 0 0 0 0 1
treated patients, treated t tr tre trea BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 10 ,[ 2 10 0 0 0 0 1
range (IQR)] range r ra ran rang BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 10 ()].(.;.). 10 10 0 0 0 0 1
(140.0; 693.0) (140.0; ( (1 (14 (140 BLOCKEND PAGEEND SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 3 10 (.;.)/ 6 8 0 0 0 0 1
2431 2431 2431 2 24 243 2431 BLOCKSTART PAGESTART NEWFONT LOWERFONT 0 0 NOCAPS ALLDIGIT 0 0 0 0 1 0 0 0 3 0 no 0 1 0 1 0 0 1
Dermatol Ther dermatol D De Der Derm BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 3 0 ()():- 6 10 0 1 1 0 1
baseline serum baseline b ba bas base BLOCKSTART PAGEIN NEWFONT HIGHERFONT 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 3 0 / 1 9 0 0 0 0 1
mL, respectively. ml, m mL mL, mL, BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 3 0 ,.-, 4 10 0 0 0 0 1
baseline median baseline b ba bas base BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 3 0 ().(.;.) 8 9 0 0 0 0 1
and 305.0 and a an and and BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 0 .(.;.)/ 7 9 0 0 0 0 1
with baseline with w wi wit with BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 1 , 1 10 0 0 0 0 1
respectively (Table respectively r re res resp BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 1 ().- 4 9 0 0 0 0 1
graphics (Table graphics g gr gra grap BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 1 () 2 9 0 0 0 0 1
(Table 2) (table ( (T (Ta (Tab BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 3 1 () 2 9 0 0 0 0 1
Table 1 table T Ta Tab Tabl BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 3 1 no 0 10 0 1 0 0 1
BMI body bmi B BM BMI BMI BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 1 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 3 1 ,,,,() 6 9 0 0 0 0 1
of participants, of o of of of BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 1 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 1 , 1 3 0 0 0 0 1
a Data a a a a a BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 1 NOCAPS NODIGIT 1 0 1 0 0 0 0 0 3 1 no 0 10 0 0 0 0 1
b Includes b b b b b BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 1 NOCAPS NODIGIT 1 0 0 0 0 0 0 0 3 1 ,, 2 8 0 0 0 0 1
Baseline IgE baseline B Ba Bas Base BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 3 3 / 1 10 0 1 0 0 1
(N = (n ( (N (N (N BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 3 3 () 2 3 0 1 0 0 1
Baseline IgE baseline B Ba Bas Base BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 3 3 / 1 10 0 1 0 0 1
(N = (n ( (N (N (N BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 3 3 () 2 3 0 1 0 0 1
Overall Overall overall O Ov Ove Over BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 3 3 no 0 10 0 1 0 0 1
Placebo Placebo placebo P Pl Pla Plac BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 3 3 no 0 7 0 1 0 0 1
(N = (n ( (N (N (N BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 3 3 () 2 10 0 1 0 0 1
Dupilumab Dupilumab dupilumab D Du Dup Dupi BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 3 3 no 0 9 0 1 0 0 1
(N = (n ( (N (N (N BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 3 3 () 2 10 0 1 0 0 1
Placebo Placebo placebo P Pl Pla Plac BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 3 3 no 0 7 0 1 0 0 1
(N = (n ( (N (N (N BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 3 3 () 2 10 0 1 0 0 1
Dupilumab Dupilumab dupilumab D Du Dup Dupi BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 3 3 no 0 9 0 1 0 0 1
(N = (n ( (N (N (N BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 3 3 () 2 10 0 1 0 0 1
Placebo Placebo placebo P Pl Pla Plac BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 3 3 no 0 8 0 1 0 0 1
(N = (n ( (N (N (N BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 3 3 () 2 10 0 1 0 0 1
Dupilumab Dupilumab dupilumab D Du Dup Dupi BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 3 4 no 0 10 0 1 0 0 1
(N = (n ( (N (N (N BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 3 4 () 2 9 0 1 0 0 1
Age (years), age A Ag Age Age BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 3 4 (), 3 10 0 0 0 0 1
mean (SD) mean m me mea mean BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 4 () 2 7 0 0 0 0 1
42.4 (14.2) 42.4 4 42 42. 42.4 BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 3 4 .(.) 4 10 0 0 0 0 1
39.8 (17.2) 39.8 3 39 39. 39.8 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 3 4 .(.) 4 10 0 0 0 0 1
41.1 (15.7) 41.1 4 41 41. 41.1 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 3 4 .(.) 4 10 0 0 0 0 1
41.8 (15.9) 41.8 4 41 41. 41.8 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 3 4 .(.) 4 10 0 0 0 0 1
41.9 (14.8) 41.9 4 41 41. 41.9 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 3 4 .(.) 4 10 0 0 0 0 1
40.7 (16.2) 40.7 4 40 40. 40.7 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 3 4 .(.) 4 10 0 0 0 0 1
Age ≥ age A Ag Age Age BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 3 4 , 1 10 0 0 0 0 1
n (%) n n n n n BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 1 0 0 0 0 0 0 0 3 4 () 2 3 0 0 0 0 1
34 (100) 34 3 34 34 34 BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 3 5 () 2 9 0 0 0 0 1
29 (93.5) 29 2 29 29 29 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 3 5 (.) 3 10 0 0 0 0 1
29 (93.5) 29 2 29 29 29 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 3 5 (.) 3 10 0 0 0 0 1
34 (97.1) 34 3 34 34 34 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 3 5 (.) 3 10 0 0 0 0 1
66 (97.1) 66 6 66 66 66 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 3 5 (.) 3 10 0 0 0 0 1
66 (94.3) 66 6 66 66 66 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 3 5 (.) 3 10 0 0 0 0 1
Age ≥ age A Ag Age Age BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 3 5 no 0 10 0 0 0 0 1
years, n years, y ye yea year BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 5 ,() 3 7 0 0 0 0 1
0 0 0 0 0 0 0 BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 3 5 no 0 2 0 0 0 0 1
1 (3.2) 1 1 1 1 1 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 3 5 (.) 3 10 0 0 0 0 1
2 (6.5) 2 2 2 2 2 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 3 5 (.) 3 10 0 0 0 0 1
0 0 0 0 0 0 0 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 3 5 no 0 2 0 0 0 0 1
2 (2.9) 2 2 2 2 2 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 3 5 (.) 3 10 0 0 0 0 1
2 (2.9) 2 2 2 2 2 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 3 5 (.) 3 10 0 0 0 0 1
Age ≥ age A Ag Age Age BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 3 6 no 0 10 0 0 0 0 1
years n years y ye yea year BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 6 () 2 7 0 0 0 0 1
0 0 0 0 0 0 0 BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 3 6 no 0 2 0 0 0 0 1
1 (3.2) 1 1 1 1 1 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 3 6 (.) 3 10 0 0 0 0 1
0 0 0 0 0 0 0 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 3 6 no 0 2 0 0 0 0 1
1 (2.9) 1 1 1 1 1 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 3 6 (.) 3 10 0 0 0 0 1
0 0 0 0 0 0 0 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 3 6 no 0 2 0 0 0 0 1
2 (2.9) 2 2 2 2 2 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 3 6 (.) 3 10 0 0 0 0 1
Female, n female, F Fe Fem Fema BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 3 6 ,() 3 10 0 0 0 0 1
27 (79.4) 27 2 27 27 27 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 3 6 (.) 3 7 0 0 0 0 1
19 (61.3) 19 1 19 19 19 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 3 6 (.) 3 7 0 0 0 0 1
21 (67.7) 21 2 21 21 21 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 3 6 (.) 3 7 0 0 0 0 1
20 (57.1) 20 2 20 20 20 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 3 6 (.) 3 7 0 0 0 0 1
50 (73.5) 50 5 50 50 50 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 3 6 (.) 3 7 0 0 0 0 1
41 (58.6) 41 4 41 41 41 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 3 6 (.) 3 7 0 0 0 0 1
Race, n race, R Ra Rac Race BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 4 7 ,() 3 10 0 0 0 0 1
White White white W Wh Whi Whit BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 1 1 0 0 0 0 0 4 7 no 0 6 0 0 0 0 1
28 (82.4) 28 2 28 28 28 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 4 7 (.) 3 10 0 0 0 0 1
23 (74.2) 23 2 23 23 23 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 4 7 (.) 3 10 0 0 0 0 1
17 (54.8) 17 1 17 17 17 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 4 7 (.) 3 10 0 0 0 0 1
21 (60.0) 21 2 21 21 21 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 4 7 (.) 3 10 0 0 0 0 1
48 (70.6) 48 4 48 48 48 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 4 7 (.) 3 10 0 0 0 0 1
47 (67.1) 47 4 47 47 47 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 4 7 (.) 3 10 0 0 0 0 1
Black or black B Bl Bla Blac BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 1 1 0 0 0 0 0 4 7 - 1 10 0 0 0 0 1
can American can c ca can can BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 7 no 0 9 0 0 0 0 1
0 0 0 0 0 0 0 BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 4 7 no 0 2 0 0 0 0 1
0 0 0 0 0 0 0 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 4 7 no 0 2 0 0 0 0 1
2 (6.5) 2 2 2 2 2 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 4 7 (.) 3 10 0 0 0 0 1
1 (2.9) 1 1 1 1 1 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 4 7 (.) 3 10 0 0 0 0 1
2 (2.9) 2 2 2 2 2 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 4 7 (.) 3 10 0 0 0 0 1
1 (1.4) 1 1 1 1 1 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 4 7 (.) 3 10 0 0 0 0 1
Asian Asian asian A As Asi Asia BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 4 8 no 0 6 0 0 0 0 1
6 (17.6) 6 6 6 6 6 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 4 8 (.) 3 9 0 0 0 0 1
7 (22.6) 7 7 7 7 7 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 4 8 (.) 3 9 0 0 0 0 1
10 (32.3) 10 1 10 10 10 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 4 8 (.) 3 10 0 0 0 0 1
12 (34.3) 12 1 12 12 12 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 4 8 (.) 3 10 0 0 0 0 1
16 (23.5) 16 1 16 16 16 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 4 8 (.) 3 10 0 0 0 0 1
19 (27.1) 19 1 19 19 19 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 4 8 (.) 3 10 0 0 0 0 1
Other b other O Ot Oth Othe BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 4 8 no 0 10 0 0 0 0 1
0 0 0 0 0 0 0 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 4 8 no 0 2 0 0 0 0 1
1 (3.2) 1 1 1 1 1 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 4 8 (.) 3 10 0 0 0 0 1
2 (6.4) 2 2 2 2 2 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 4 8 (.) 3 10 0 0 0 0 1
1 (2.9) 1 1 1 1 1 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 4 8 (.) 3 10 0 0 0 0 1
2 (2.9) 2 2 2 2 2 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 4 8 (.) 3 10 0 0 0 0 1
3 (4.3) 3 3 3 3 3 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 4 8 (.) 3 10 0 0 0 0 1
Weight (kg), weight W We Wei Weig BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 4 9 (), 3 10 0 0 0 0 1
mean (SD) mean m me mea mean BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 9 () 2 7 0 0 0 0 1
75.3 (20.3) 75.3 7 75 75. 75.3 BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 4 9 .(.) 4 10 0 0 0 0 1
73.3 (20.0) 73.3 7 73 73. 73.3 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 4 9 .(.) 4 10 0 0 0 0 1
75.8(16.5) 75.8(16.5) 75.8(16.5) 7 75 75. 75.8 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 4 9 .(.) 4 9 0 0 0 0 1
80.6 (21.5) 80.6 8 80 80. 80.6 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 4 9 .(.) 4 10 0 0 0 0 1
75.8 (18.4) 75.8 7 75 75. 75.8 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 4 9 .(.) 4 10 0 0 0 0 1
77.2 (21.5) 77.2 7 77 77. 77.2 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 4 9 .(.) 4 10 0 0 0 0 1
BMI (kg/m bmi B BM BMI BMI BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 4 10 (/), 4 10 0 0 0 0 1
mean (SD) mean m me mea mean BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 10 () 2 6 0 0 0 0 1
27.7 (6.8) 27.7 2 27 27. 27.7 BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 4 10 .(.) 4 9 0 0 0 0 1
26.1 (5.5) 26.1 2 26 26. 26.1 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 4 10 .(.) 4 9 0 0 0 0 1
27.9 (5.6) 27.9 2 27 27. 27.9 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 4 10 .(.) 4 9 0 0 0 0 1
28.82 (7.6) 28.82 2 28 28. 28.8 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 4 10 .(.) 4 10 0 0 0 0 1
27.9 (6.2) 27.9 2 27 27. 27.9 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 4 10 .(.) 4 9 0 0 0 0 1
27.4 (6.8) 27.4 2 27 27. 27.4 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 4 10 .(.) 4 9 0 0 0 0 1
Baseline serum baseline B Ba Bas Base BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 4 10 no 0 10 0 0 0 0 1
total IgE total t to tot tota BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 10 (/ 2 10 0 0 0 0 1
mL), median ml), m mL mL) mL), BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 4 10 ), 2 8 0 0 0 0 1
(IQR) a (iqr) ( (I (IQ (IQR BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 4 10 () 2 5 0 0 0 0 1
29.0 (14.3; 29.0 2 29 29. 29.0 BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 4 11 .(.;.).(.;.).(.; 16 10 0 0 0 0 1
693.0) 693.0) 693.0) 6 69 693 693. BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 4 11 .) 2 1 0 0 0 0 1
305.0 (169.5; 305.0 3 30 305 305. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 4 11 .(.; 4 10 0 0 0 0 1
606.0) 606.0) 606.0) 6 60 606 606. BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 4 11 .) 2 5 0 0 0 0 1
96.5 (27.9; 96.5 9 96 96. 96.5 BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 4 11 .(.; 4 10 0 0 0 0 1
221.0) 221.0) 221.0) 2 22 221 221. BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 4 11 .) 2 5 0 0 0 0 1
109.4 (49.2; 109.4 1 10 109 109. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 4 11 .(.; 4 10 0 0 0 0 1
381.0) 381.0) 381.0) 3 38 381 381. BLOCKEND PAGEEND SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 4 11 .) 2 5 0 0 0 0 1
2432 2432 2432 2 24 243 2432 BLOCKSTART PAGESTART NEWFONT LOWERFONT 0 0 NOCAPS ALLDIGIT 0 0 0 0 1 0 0 0 4 0 no 0 10 0 1 0 0 1
Dermatol Ther dermatol D De Der Derm BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 4 0 ()():- 6 10 0 1 1 0 1
between baseline between b be bet betw BLOCKSTART PAGEIN NEWFONT HIGHERFONT 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 0 . 1 10 0 0 0 0 1
the subgroup the t th the the BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 0 /, 2 9 0 0 0 0 1
baseline UAS7 baseline b ba bas base BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 4 0 - 1 9 0 0 0 0 1
versus placebo-treated versus v ve ver vers BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 0 -, 2 9 0 0 0 0 1
proportion of proportion p pr pro prop BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 0 -- 2 9 0 0 0 0 1
cebo-treated patients cebo-treated c ce ceb cebo BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 4 0 -(..) 5 10 0 0 0 0 1
a baseline a a a a a BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 1 0 1 0 0 0 0 0 4 0 . 1 5 0 0 0 0 1
Treatment with treatment T Tr Tre Trea BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 1 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 4 1 no 0 10 0 0 0 0 1
Total IgE total T To Tot Tota BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 4 1 no 0 9 0 0 0 0 1
Regardless of regardless R Re Reg Rega BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 1 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 4 1 no 0 10 0 0 0 0 1
Treatment with treatment T Tr Tre Trea BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 4 1 no 0 8 0 0 0 0 1
reduction from reduction r re red redu BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 1 no 0 8 0 0 0 0 1
IgE versus ige I Ig IgE IgE BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 4 1 , 1 9 0 0 0 0 1
12 (dupilumab: 12 1 12 12 12 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 4 1 (:-.;:-.) 9 8 0 0 0 0 1
week 24 week w we wee week BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 1 (:-.;:-.) 9 8 0 0 0 0 1
[16] (See [16] [ [1 [16 [16] BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 4 1 []( 3 9 0 0 0 0 1
material for material m ma mat mate BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 1 .). 3 10 0 0 0 0 1
IgE reduction ige I Ig IgE IgE BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 4 1 no 0 9 0 0 0 0 1
in dupilumab-treated in i in in in BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 4 1 - 1 8 0 0 0 0 1
week 24 week w we wee week BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 1 , 1 9 0 0 0 0 1
with more with w wi wit with BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 1 no 0 8 0 0 0 0 1
IgE observed ige I Ig IgE IgE BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 4 1 - 1 8 0 0 0 0 1
week 24 week w we wee week BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 1 (.). 4 6 0 0 0 0 1
Treatment with treatment T Tr Tre Trea BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 1 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 4 3 , 1 10 0 0 0 0 1
UAS7, and uas7, U UA UAS UAS7 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 4 3 , 1 9 0 0 0 0 1
Regardless of regardless R Re Reg Rega BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 1 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 4 3 no 0 9 0 0 0 0 1
In LIBERTY-CSU in I In In In BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 1 1 0 0 0 0 0 4 3 -, 2 9 0 0 0 0 1
with dupilumab with w wi wit with BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 3 ()- 3 9 0 0 0 0 1
nificantly greater nificantly n ni nif nifi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 4 3 no 0 8 0 0 0 0 1
at week at a at at at BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 3 (.)(.) 6 9 0 0 0 0 1
[16]. In [16]. [ [1 [16 [16] BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 4 3 [].-,- 6 8 0 0 0 0 1
ment in ment m me men ment BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 4 3 no 0 9 0 0 0 0 1
serum total serum s se ser seru BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 3 (- 2 8 0 0 0 0 1
group: -8.8, group: g gr gro grou BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 3 :-.,:-., 8 9 0 0 0 0 1
p = p p p p p BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 1 0 0 0 0 0 0 0 4 3 .)(:-., 7 9 0 0 0 0 1
subgroup: -11.2, subgroup: s su sub subg BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 3 :-.,.)(.,). 11 10 0 0 0 0 1
Similarly, significant similarly, S Si Sim Simi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 4 3 , 1 7 0 0 0 0 1
observed in observed o ob obs obse BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 3 - 1 8 0 0 0 0 1
patients versus patients p pa pat pati BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 3 - 1 7 0 0 0 0 1
at both at a at at at BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 3 (.) 3 7 0 0 0 0 1
(p = (p ( (p (p (p BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 4 3 (.)[]. 6 9 0 0 0 0 1
independent of independent i in ind inde BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 6 no 0 9 0 0 0 0 1
in dupilumab-treated in i in in in BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 4 6 - 1 9 0 0 0 0 1
(< 100 (< ( (< (< (< BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 4 6 (:-.,:-., 9 9 0 0 0 0 1
interaction p interaction i in int inte BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 4 6 .)(- 4 9 0 0 0 0 1
group: -19.5, group: g gr gro grou BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 6 :-.,:-., 8 10 0 0 0 0 1
p = p p p p p BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 1 0 0 0 0 0 0 0 4 6 .)(.,). 7 4 0 0 0 0 1
Improvements were improvements I Im Imp Impr BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 4 6 no 0 8 0 0 0 0 1
scores in scores s sc sco scor BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 6 -- 2 8 0 0 0 0 1
sus placebo-treated sus s su sus sus BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 4 6 - 1 9 0 0 0 0 1
(nominal p (nominal ( (n (no (nom BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 4 6 (.)(.) 6 9 0 0 0 0 1
[16], and [16], [ [1 [16 [16] BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 4 6 [],- 4 8 0 0 0 0 1
pendent of pendent p pe pen pend BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 4 6 no 0 9 0 0 0 0 1
dupilumab-treated patients dupilumab-treated d du dup dupi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 4 6 - 1 8 0 0 0 0 1
(< 100 (< ( (< (< (< BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 4 6 (:-.,:-., 9 9 0 0 0 0 1
interaction p interaction i in int inte BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 4 6 .)(- 4 9 0 0 0 0 1
group: -9.7, group: g gr gro grou BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 6 :-.,:-., 8 9 0 0 0 0 1
p = p p p p p BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 1 0 0 0 0 0 0 0 4 6 .)(.,). 7 4 0 0 0 0 1
Weak Correlations weak W We Wea Weak BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 1 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 5 9 no 0 9 0 0 0 0 1
and ISS7, and a an and and BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 9 ,, 2 10 0 0 0 0 1
12 and 12 1 12 12 12 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 5 9 no 0 3 0 0 0 0 1
Weak correlations weak W We Wea Weak BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 5 9 (.) 3 9 0 0 0 0 1
between change between b be bet betw BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 9 no 0 10 0 0 0 0 1
ISS7, UAS7, iss7, I IS ISS ISS7 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 5 9 ,, 2 10 0 0 0 0 1
(Table 3). (table ( (T (Ta (Tab BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 5 9 (). 3 2 0 0 0 0 1
Safety Safety safety S Sa Saf Safe BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 1 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 5 10 no 0 10 0 0 0 0 1
Safety analyses safety S Sa Saf Safe BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 5 10 no 0 9 0 0 0 0 1
from LIBERTY-CSU from f fr fro from BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 10 -[ 2 8 0 0 0 0 1
(n = (n ( (n (n (n BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 5 10 ()()]., 7 9 0 0 0 0 1
safety analyses safety s sa saf safe BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 10 no 0 9 0 0 0 0 1
the stratified the t th the the BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 10 no 0 10 0 0 0 0 1
[< 100 [< [ [< [< [< BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 5 10 [:()- 5 9 0 0 0 0 1
cebo (n cebo c ce ceb cebo BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 5 10 ();:() 6 9 0 0 0 0 1
versus placebo versus v ve ver vers BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 10 ()]. 4 9 0 0 0 0 1
58.8% of 58.8% 5 58 58. 58.8 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 5 10 .-. 3 9 0 0 0 0 1
dupilumab-treated patients dupilumab-treated d du dup dupi BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 5 10 -(). 4 7 0 0 0 0 1
DISCUSSION DISCUSSION discussion D DI DIS DISC BLOCKSTART PAGEIN NEWFONT HIGHERFONT 0 0 ALLCAP NODIGIT 0 0 1 0 0 0 0 0 5 11 no 0 10 0 0 0 0 1
This analysis this T Th Thi This BLOCKSTART PAGEIN NEWFONT LOWERFONT 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 5 11 - 1 10 0 0 0 0 1
demonstrated that demonstrated d de dem demo BLOCKEND PAGEEND SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 11 no 0 10 0 0 0 0 1
2433 2433 2433 2 24 243 2433 BLOCKSTART PAGESTART NEWFONT LOWERFONT 0 0 NOCAPS ALLDIGIT 0 0 0 0 1 0 0 0 5 0 no 0 1 0 1 0 0 1
Dermatol Ther dermatol D De Der Derm BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 5 0 ()():- 6 10 0 1 1 0 1
Table 2 table T Ta Tab Tabl BLOCKSTART PAGEIN NEWFONT HIGHERFONT 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 5 0 no 0 10 0 1 0 0 1
Baseline IgE baseline B Ba Bas Base BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 5 0 / 1 10 0 1 0 0 1
(N = (n ( (N (N (N BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 5 0 () 2 3 0 1 0 0 1
Baseline IgE baseline B Ba Bas Base BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 5 0 / 1 10 0 1 0 0 1
(N = (n ( (N (N (N BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 5 0 () 2 3 0 1 0 0 1
Overall (N overall O Ov Ove Over BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 5 0 () 2 10 0 1 0 0 1
Placebo Placebo placebo P Pl Pla Plac BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 5 1 no 0 7 0 1 0 0 1
(N = (n ( (N (N (N BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 5 1 () 2 10 0 1 0 0 1
Dupilumab Dupilumab dupilumab D Du Dup Dupi BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 5 1 no 0 9 0 1 0 0 1
(N = (n ( (N (N (N BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 5 1 () 2 10 0 1 0 0 1
Placebo Placebo placebo P Pl Pla Plac BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 5 1 no 0 7 0 1 0 0 1
(N = (n ( (N (N (N BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 5 1 () 2 10 0 1 0 0 1
Dupilumab Dupilumab dupilumab D Du Dup Dupi BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 5 1 no 0 9 0 1 0 0 1
(N = (n ( (N (N (N BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 5 1 () 2 10 0 1 0 0 1
Placebo Placebo placebo P Pl Pla Plac BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 5 1 no 0 8 0 1 0 0 1
(N = (n ( (N (N (N BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 5 1 () 2 10 0 1 0 0 1
Dupilumab Dupilumab dupilumab D Du Dup Dupi BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 5 1 no 0 10 0 1 0 0 1
(N = (n ( (N (N (N BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 5 1 () 2 9 0 1 0 0 1
Age at age A Ag Age Age BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 5 2 no 0 10 0 0 0 0 1
CSU (years), csu C CS CSU CSU BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 5 2 (), 3 8 0 0 0 0 1
mean (SD) mean m me mea mean BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 2 () 2 6 0 0 0 0 1
36.6 (15.6) 36.6 3 36 36. 36.6 BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 5 2 .(.) 4 10 0 0 0 0 1
32.7 (17.1) 32.7 3 32 32. 32.7 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 5 2 .(.) 4 10 0 0 0 0 1
36.7 (17.0) 36.7 3 36 36. 36.7 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 5 2 .(.) 4 10 0 0 0 0 1
38.1 (16.4) 38.1 3 38 38. 38.1 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 5 2 .(.) 4 10 0 0 0 0 1
36.7 (16.0) 36.7 3 36 36. 36.7 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 5 2 .(.) 4 10 0 0 0 0 1
35.5 (16.6) 35.5 3 35 35. 35.5 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 5 2 .(.) 4 10 0 0 0 0 1
Time since time T Ti Tim Time BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 5 3 no 0 10 0 0 0 0 1
diagnosis of diagnosis d di dia diag BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 3 no 0 7 0 0 0 0 1
CSU (years), csu C CS CSU CSU BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 5 3 (), 3 7 0 0 0 0 1
mean (SD) mean m me mea mean BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 3 () 2 5 0 0 0 0 1
6.3 (8.6) 6.3 6 6. 6.3 6.3 BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 5 3 .(.) 4 9 0 0 0 0 1
7.7 (12.1) 7.7 7 7. 7.7 7.7 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 5 3 .(.) 4 10 0 0 0 0 1
5.0 (7.0) 5.0 5 5. 5.0 5.0 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 5 3 .(.) 4 9 0 0 0 0 1
4.3 (6.4) 4.3 4 4. 4.3 4.3 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 5 3 .(.) 4 9 0 0 0 0 1
5.7 (7.7) 5.7 5 5. 5.7 5.7 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 5 3 .(.) 4 9 0 0 0 0 1
5.8 (9.3) 5.8 5 5. 5.8 5.8 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 5 3 .(.) 4 9 0 0 0 0 1
Baseline ISS7 baseline B Ba Bas Base BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 5 4 no 0 10 0 0 0 0 1
score, mean score, s sc sco scor BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 4 , 1 8 0 0 0 0 1
(SD) (SD) (sd) ( (S (SD (SD) BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 5 4 () 2 3 0 0 0 0 1
16.5 (4.1) 16.5 1 16 16. 16.5 BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 5 4 .(.) 4 10 0 0 0 0 1
15.5 (4.3) 15.5 1 15 15. 15.5 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 5 4 .(.) 4 10 0 0 0 0 1
15.3 (4.1) 15.3 1 15 15. 15.3 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 5 4 .(.) 4 10 0 0 0 0 1
16.7 (3.8) 16.7 1 16 16. 16.7 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 5 4 .(.) 4 10 0 0 0 0 1
15.7 (4.1) 15.7 1 15 15. 15.7 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 5 4 .(.) 4 10 0 0 0 0 1
16.1 (4.0) 16.1 1 16 16. 16.1 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 5 4 .(.) 4 10 0 0 0 0 1
Baseline UAS7 baseline B Ba Bas Base BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 5 5 no 0 10 0 0 0 0 1
score, mean score, s sc sco scor BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 5 , 1 8 0 0 0 0 1
(SD) (SD) (sd) ( (S (SD (SD) BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 5 5 () 2 3 0 0 0 0 1
31.7 (8.3) 31.7 3 31 31. 31.7 BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 5 5 .(.) 4 10 0 0 0 0 1
30.1 (8.2) 30.1 3 30 30. 30.1 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 5 5 .(.) 4 10 0 0 0 0 1
30.0 (8.3) 30.0 3 30 30. 30.0 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 5 5 .(.) 4 10 0 0 0 0 1
33.6 (6.0) 33.6 3 33 33. 33.6 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 5 5 .(.) 4 10 0 0 0 0 1
30.8 (8.2) 30.8 3 30 30. 30.8 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 5 5 .(.) 4 10 0 0 0 0 1
31.9 (7.2) 31.9 3 31 31. 31.9 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 5 5 .(.) 4 10 0 0 0 0 1
Baseline UAS7 baseline B Ba Bas Base BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 5 6 no 0 10 0 0 0 0 1
score < score s sc sco scor BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 6 , 1 10 0 0 0 0 1
(%) (%) (%) ( (% (%) (%) BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 5 6 () 2 2 0 0 0 0 1
9 (26.5) 9 9 9 9 9 BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 5 6 (.) 3 9 0 0 0 0 1
10 (32.3) 10 1 10 10 10 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 5 6 (.) 3 10 0 0 0 0 1
13 (41.9) 13 1 13 13 13 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 5 6 (.) 3 10 0 0 0 0 1
5 (14.3) 5 5 5 5 5 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 5 6 (.) 3 9 0 0 0 0 1
24 (35.3) 24 2 24 24 24 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 5 6 (.) 3 10 0 0 0 0 1
17 (24.3) 17 1 17 17 17 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 5 6 (.) 3 10 0 0 0 0 1
Baseline UAS7 baseline B Ba Bas Base BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 5 7 no 0 10 0 0 0 0 1
score ≥ score s sc sco scor BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 7 , 1 10 0 0 0 0 1
(%) (%) (%) ( (% (%) (%) BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 5 7 () 2 2 0 0 0 0 1
25 (73.5) 25 2 25 25 25 BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 5 7 (.) 3 10 0 0 0 0 1
21 (67.7) 21 2 21 21 21 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 5 7 (.) 3 10 0 0 0 0 1
18 (58.1) 18 1 18 18 18 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 5 7 (.) 3 10 0 0 0 0 1
30 (85.7) 30 3 30 30 30 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 5 7 (.) 3 10 0 0 0 0 1
44 (64.7) 44 4 44 44 44 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 5 7 (.) 3 10 0 0 0 0 1
53 (75.7) 53 5 53 53 53 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 5 7 (.) 3 10 0 0 0 0 1
Baseline HSS7 baseline B Ba Bas Base BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 5 7 no 0 10 0 0 0 0 1
score, mean score, s sc sco scor BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 7 , 1 8 0 0 0 0 1
(SD) (SD) (sd) ( (S (SD (SD) BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 5 7 () 2 3 0 0 0 0 1
15.2 (5.1) 15.2 1 15 15. 15.2 BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 5 8 .(.) 4 10 0 0 0 0 1
14.6 (4.3) 14.6 1 14 14. 14.6 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 5 8 .(.) 4 10 0 0 0 0 1
14.7 (4.6) 14.7 1 14 14. 14.7 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 5 8 .(.) 4 10 0 0 0 0 1
16.9 (3.1) 16.9 1 16 16. 16.9 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 5 8 .(.) 4 10 0 0 0 0 1
15.0 (4.8) 15.0 1 15 15. 15.0 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 5 8 .(.) 4 10 0 0 0 0 1
15.8 (3.8) 15.8 1 15 15. 15.8 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 5 8 .(.) 4 10 0 0 0 0 1
Presence of presence P Pr Pre Pres BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 5 8 no 0 8 0 0 0 0 1
angioedema angioedema angioedema a an ang angi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 5 8 no 0 7 0 0 0 0 1
at baseline, at a at at at BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 8 , 1 10 0 0 0 0 1
(%) b (%) ( (% (%) (%) BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 5 8 () 2 4 0 0 0 0 1
18 (52.9) 18 1 18 18 18 BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 5 9 (.) 3 8 0 0 0 0 1
13.0 (41.9) 13.0 1 13 13. 13.0 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 5 9 .(.) 4 10 0 0 0 0 1
15 (48.4) 15 1 15 15 15 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 5 9 (.) 3 8 0 0 0 0 1
14 (40.0) 14 1 14 14 14 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 5 9 (.) 3 8 0 0 0 0 1
34 (50.0) 34 3 34 34 34 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 5 9 (.) 3 8 0 0 0 0 1
28 (40.0) 28 2 28 28 28 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 5 9 (.) 3 8 0 0 0 0 1
Baseline AAS7 baseline B Ba Bas Base BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 5 9 no 0 9 0 0 0 0 1
score for score s sc sco scor BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 9 - 1 9 0 0 0 0 1
ticipants with ticipants t ti tic tici BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 5 9 no 0 10 0 0 0 0 1
angioedema, angioedema, angioedema, a an ang angi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 5 9 , 1 8 0 0 0 0 1
mean (SD) mean m me mea mean BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 9 () 2 6 0 0 0 0 1
38.5 (27.9) 38.5 3 38 38. 38.5 BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 5 10 .(.) 4 10 0 0 0 0 1
34.5 (27.6) 34.5 3 34 34. 34.5 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 5 10 .(.) 4 10 0 0 0 0 1
32.7 (27.8) 32.7 3 32 32. 32.7 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 5 10 .(.) 4 10 0 0 0 0 1
29.6 (20.0) 29.6 2 29 29. 29.6 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 5 10 .(.) 4 10 0 0 0 0 1
35.3 (27.4) 35.3 3 35 35. 35.3 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 5 10 .(.) 4 10 0 0 0 0 1
32.1 32.1 32.1 3 32 32. 32.1 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 5 10 . 1 4 0 0 0 0 1
(23.2) (23.2) (23.2) ( (2 (23 (23. BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 5 10 (.) 3 5 0 0 0 0 1
Baseline UCT baseline B Ba Bas Base BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 5 11 no 0 10 0 0 0 0 1
score, mean score, s sc sco scor BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 11 , 1 9 0 0 0 0 1
(SD) (SD) (sd) ( (S (SD (SD) BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 5 11 () 2 3 0 0 0 0 1
3.4 (2.3) 3.4 3 3. 3.4 3.4 BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 5 11 .(.) 4 10 0 0 0 0 1
3.5 (2.0) 3.5 3 3. 3.5 3.5 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 5 11 .(.) 4 10 0 0 0 0 1
3.8 (2.2) 3.8 3 3. 3.8 3.8 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 5 11 .(.) 4 10 0 0 0 0 1
3.9 (2.5) 3.9 3 3. 3.9 3.9 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 5 11 .(.) 4 10 0 0 0 0 1
3.6 (2.3) 3.6 3 3. 3.6 3.6 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 5 11 .(.) 4 10 0 0 0 0 1
3.8 (2.3) 3.8 3 3. 3.8 3.8 BLOCKEND PAGEEND SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 5 11 .(.) 4 10 0 0 0 0 1
2434 2434 2434 2 24 243 2434 BLOCKSTART PAGESTART NEWFONT LOWERFONT 0 0 NOCAPS ALLDIGIT 0 0 0 0 1 0 0 0 5 0 no 0 10 0 1 0 0 1
Dermatol Ther dermatol D De Der Derm BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 5 0 ()():- 6 10 0 1 1 0 1
with a with w wi wit with BLOCKSTART PAGEIN NEWFONT HIGHERFONT 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 0 no 0 9 0 0 0 0 1
in patients in i in in in BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 5 0 --, 3 9 0 0 0 0 1
of baseline of o of of of BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 0 . 1 10 0 0 0 0 1
in serum in i in in in BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 5 0 no 0 8 0 0 0 0 1
in patients in i in in in BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 5 0 - 1 9 0 0 0 0 1
ies reporting ies i ie ies ies BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 5 0 no 0 9 0 0 0 0 1
atopic dermatitis, atopic a at ato atop BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 5 0 , 1 9 0 0 0 0 1
nasal polyps, nasal n na nas nasa BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 0 ,, 2 9 0 0 0 0 1
asthma who asthma a as ast asth BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 0 no 0 7 0 0 0 0 1
[17-20, 26, [17-20, [ [1 [17 [17- BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 6 1 [-,,]. 6 9 0 0 0 0 1
total IgE total t to tot tota BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 1 no 0 9 0 0 0 0 1
result from result r re res resu BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 1 -/-- 4 9 0 0 0 0 1
B-cell proliferation b-cell B B- B-c B-ce BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 6 1 - 1 9 0 0 0 0 1
[28]. [28]. [28]. [ [2 [28 [28] BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 6 1 []. 3 1 0 0 0 0 1
Furthermore, dupilumab furthermore, F Fu Fur Furt BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 6 1 ,- 2 8 0 0 0 0 1
icant improvements icant i ic ica ican BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 6 1 no 0 9 0 0 0 0 1
of CSU, of o of of of BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 1 ,,,, 4 9 0 0 0 0 1
regardless of regardless r re reg rega BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 1 ., 2 10 0 0 0 0 1
Unless otherwise unless U Un Unl Unle BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 6 2 ,--, 4 10 0 0 0 0 1
randomized participants. randomized r ra ran rand BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 6 2 ./,, 4 9 0 0 0 0 1
indicate higher indicate i in ind indi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 2 no 0 2 0 0 0 0 1
AAS7 Angioedema aas7 A AA AAS AAS7 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 6 2 (-),'(-), 9 8 0 0 0 0 1
chronic spontaneous chronic c ch chr chro BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 2 ,(-),--, 8 8 0 0 0 0 1
HSS7 Hives hss7 H HS HSS HSS7 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 6 2 (-),,, 6 9 0 0 0 0 1
7 days 7 7 7 7 7 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 6 2 (-),(),(-), 11 9 0 0 0 0 1
deviation, UAS7 deviation, d de dev devi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 2 ,(-),(-) 8 7 0 0 0 0 1
a Data a a a a a BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 1 0 1 0 0 0 0 0 6 2 no 0 10 0 0 0 0 1
b Participants b b b b b BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 1 0 0 0 0 0 0 0 6 2 no 0 3 0 0 0 0 1
c Excludes c c c c c BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 1 0 0 0 0 0 0 0 6 2 /,, 3 8 0 0 0 0 1
child who child c ch chi chil BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 6 2 no 0 3 0 0 0 0 1
d Standard d d d d d BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 1 0 0 0 0 0 0 0 6 2 - 1 4 0 0 0 0 1
Table 2 table T Ta Tab Tabl BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 6 7 no 0 10 0 1 0 0 1
Baseline IgE baseline B Ba Bas Base BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 6 7 / 1 10 0 1 0 0 1
(N = (n ( (N (N (N BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 6 7 () 2 3 0 1 0 0 1
Baseline IgE baseline B Ba Bas Base BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 6 7 / 1 10 0 1 0 0 1
(N = (n ( (N (N (N BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 6 7 () 2 3 0 1 0 0 1
Overall (N overall O Ov Ove Over BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 6 7 () 2 10 0 1 0 0 1
Placebo Placebo placebo P Pl Pla Plac BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 6 7 no 0 7 0 1 0 0 1
(N = (n ( (N (N (N BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 6 7 () 2 10 0 1 0 0 1
Dupilumab Dupilumab dupilumab D Du Dup Dupi BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 6 7 no 0 9 0 1 0 0 1
(N = (n ( (N (N (N BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 6 7 () 2 10 0 1 0 0 1
Placebo Placebo placebo P Pl Pla Plac BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 6 7 no 0 7 0 1 0 0 1
(N = (n ( (N (N (N BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 6 7 () 2 10 0 1 0 0 1
Dupilumab Dupilumab dupilumab D Du Dup Dupi BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 6 8 no 0 9 0 1 0 0 1
(N = (n ( (N (N (N BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 6 8 () 2 10 0 1 0 0 1
Placebo Placebo placebo P Pl Pla Plac BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 6 8 no 0 8 0 1 0 0 1
(N = (n ( (N (N (N BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 6 8 () 2 10 0 1 0 0 1
Dupilumab Dupilumab dupilumab D Du Dup Dupi BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 6 8 no 0 10 0 1 0 0 1
(N = (n ( (N (N (N BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 6 8 () 2 9 0 1 0 0 1
Baseline DLQI baseline B Ba Bas Base BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 6 8 no 0 10 0 0 0 0 1
score, c score, s sc sco scor BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 8 , 1 10 0 0 0 0 1
(SD) (SD) (sd) ( (S (SD (SD) BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 6 8 () 2 3 0 0 0 0 1
15.8 (5.5) 15.8 1 15 15. 15.8 BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 6 8 .(.) 4 10 0 0 0 0 1
13.0 (5.7) 13.0 1 13 13. 13.0 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 6 8 .(.) 4 10 0 0 0 0 1
15.2 (7.3) 15.2 1 15 15. 15.2 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 6 8 .(.) 4 10 0 0 0 0 1
13.9 (6.2) 13.9 1 13 13. 13.9 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 6 8 .(.) 4 10 0 0 0 0 1
15.3 (6.7) 15.3 1 15 15. 15.3 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 6 8 .(.) 4 10 0 0 0 0 1
13.5 (5.9) 13.5 1 13 13. 13.5 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 6 8 .(.) 4 10 0 0 0 0 1
Baseline PGIS baseline B Ba Bas Base BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 6 9 no 0 10 0 0 0 0 1
score, mean score, s sc sco scor BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 9 , 1 8 0 0 0 0 1
(SD) (SD) (sd) ( (S (SD (SD) BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 6 9 () 2 3 0 0 0 0 1
3.4 (0.6) 3.4 3 3. 3.4 3.4 BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 6 9 .(.) 4 10 0 0 0 0 1
3.4 (0.5) 3.4 3 3. 3.4 3.4 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 6 9 .(.) 4 10 0 0 0 0 1
3.5 (0.5) 3.5 3 3. 3.5 3.5 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 6 9 .(.) 4 10 0 0 0 0 1
3.4 (0.7) 3.4 3 3. 3.4 3.4 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 6 9 .(.) 4 10 0 0 0 0 1
3.5 (0.6) 3.5 3 3. 3.5 3.5 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 6 9 .(.) 4 10 0 0 0 0 1
3.4 (0.6) 3.4 3 3. 3.4 3.4 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 6 9 .(.) 4 10 0 0 0 0 1
Baseline H1-AH, baseline B Ba Bas Base BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 6 10 -,() 4 10 0 0 0 0 1
Standard dose standard S St Sta Stan BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 6 10 (.) 3 10 0 0 0 0 1
13 (41.9) 13 1 13 13 13 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 6 10 (.) 3 3 0 0 0 0 1
21 (67.7) 21 2 21 21 21 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 6 10 (.) 3 3 0 0 0 0 1
16 (45.7) 16 1 16 16 16 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 6 10 (.) 3 3 0 0 0 0 1
41 (60.3) 41 4 41 41 41 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 6 10 (.) 3 3 0 0 0 0 1
31 (44.3) 31 3 31 31 31 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 6 10 (.) 3 3 0 0 0 0 1
2-3-fold stand- 2-3-fold 2 2- 2-3 2-3- BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS CONTAINSDIGITS 0 0 0 0 0 0 0 0 6 10 --- 3 10 0 0 0 0 1
ard dose ard a ar ard ard BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 0 0 0 0 0 0 6 10 no 0 7 0 0 0 0 1
10 (29.4) 10 1 10 10 10 BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 6 10 (.) 3 10 0 0 0 0 1
10 (32.3) 10 1 10 10 10 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 6 10 (.) 3 10 0 0 0 0 1
5 (16.1) 5 5 5 5 5 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 6 10 (.) 3 9 0 0 0 0 1
15 (42.9) 15 1 15 15 15 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 6 10 (.) 3 10 0 0 0 0 1
16 (23.5) 16 1 16 16 16 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 6 10 (.) 3 10 0 0 0 0 1
27 (38.6) 27 2 27 27 27 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 6 10 (.) 3 10 0 0 0 0 1
Fourfold stand- fourfold F Fo Fou Four BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 6 11 - 1 10 0 0 0 0 1
ard dose ard a ar ard ard BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 0 0 0 0 0 0 6 11 no 0 7 0 0 0 0 1
5 (14.7) 5 5 5 5 5 BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 6 11 (.) 3 9 0 0 0 0 1
8 (25.8) 8 8 8 8 8 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 6 11 (.) 3 9 0 0 0 0 1
5 (16.1) 5 5 5 5 5 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 6 11 (.) 3 9 0 0 0 0 1
4 (11.4) 4 4 4 4 4 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 6 11 (.) 3 9 0 0 0 0 1
11 (16.2) 11 1 11 11 11 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 6 11 (.) 3 10 0 0 0 0 1
12 (17.1) 12 1 12 12 12 BLOCKEND PAGEEND SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 6 11 (.) 3 10 0 0 0 0 1
2435 2435 2435 2 24 243 2435 BLOCKSTART PAGESTART NEWFONT LOWERFONT 0 0 NOCAPS ALLDIGIT 0 0 0 0 1 0 0 0 6 0 no 0 1 1 1 0 0 1
Dermatol Ther dermatol D De Der Derm BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 6 0 ()():- 6 10 1 1 1 0 1
weak correlation weak w we wea weak BLOCKSTART PAGEIN NEWFONT HIGHERFONT 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 0 (.) 3 9 1 0 0 0 1
IgE reduction ige I Ig IgE IgE BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 6 0 ,,- 3 8 1 0 0 0 1
comes, suggesting comes, c co com come BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 0 , 1 9 1 0 0 0 1
in CSU in i in in in BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 6 0 - 1 8 1 0 0 0 1
tion of tion t ti tio tion BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 6 0 -.- 3 8 1 0 0 0 1
ings were ings i in ing ings BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 6 0 no 0 9 1 0 0 0 1
dupilumab safety dupilumab d du dup dupi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 6 0 []. 3 9 1 0 0 0 1
these findings these t th the thes BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 0 /,- 3 9 1 0 0 0 1
line total line l li lin line BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 0 no 0 10 1 0 0 0 1
as a as a as as as BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 0 no 0 8 1 0 0 0 1
in CSU. in i in in in BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 6 0 . 1 1 1 0 0 0 1
The pathophysiology the T Th The The BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 6 0 no 0 8 1 0 0 0 1
include both include i in inc incl BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 0 (; 2 9 1 0 0 0 1
IgE autoantibodies ige I Ig IgE IgE BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 6 0 , 1 9 1 0 0 0 1
thyroglobulin, tissue thyroglobulin, t th thy thyr BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 6 0 ,,- 3 9 1 0 0 0 1
DNA, IL-24) dna, D DN DNA DNA, BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 6 0 ,-)[ 4 8 1 0 0 0 1
or immunoglobulin or o or or or BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 0 () 2 8 1 0 0 0 1
against IgE against a ag aga agai BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 0 /-, 3 9 1 0 0 0 1
FcεRI] [29-32]. fcεri] F Fc Fcε FcεR BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 6 0 ][-].- 6 9 1 0 0 0 1
vated IgE vated v va vat vate BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 6 0 /[]. 4 9 1 0 0 0 1
However, IgE however, H Ho How Howe BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 6 0 ,, 2 9 1 0 0 0 1
sex, genetic sex, s se sex sex, BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 5 ,, 2 8 1 0 0 0 1
exposure. Higher-than-normal exposure. e ex exp expo BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 5 .-- 3 9 1 0 0 0 1
have been have h ha hav have BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 5 no 0 8 1 0 0 0 1
with CSU, with w wi wit with BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 5 , 1 9 1 0 0 0 1
atopic patients atopic a at ato atop BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 6 5 , 1 9 1 0 0 0 1
status may status s st sta stat BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 5 no 0 9 1 0 0 0 1
patients with patients p pa pat pati BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 5 []. 3 9 1 0 0 0 1
with CSU with w wi wit with BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 5 , 1 10 1 0 0 0 1
long disease long l lo lon long BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 6 5 , 1 9 1 0 0 0 1
responding to responding r re res resp BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 5 , 1 9 1 0 0 0 1
omalizumab treatment omalizumab o om oma omal BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 6 5 , 1 8 1 0 0 0 1
chance of chance c ch cha chan BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 6 5 [,]. 4 8 1 0 0 0 1
In CSU, in I In In In BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 1 1 0 0 0 0 0 6 5 ,-/--- 6 8 1 0 0 0 1
liferation and liferation l li lif life BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 6 5 , 1 8 1 0 0 0 1
increased IgE increased i in inc incr BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 5 - 1 9 1 0 0 0 1
tion. However, tion. t ti tio tion BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 6 5 .,-/- 5 9 1 0 0 0 1
in direct in i in in in BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 6 5 (- 2 9 1 0 0 0 1
sion on sion s si sio sion BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 6 5 ),- 3 9 1 0 0 0 1
the skin, the t th the the BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 5 , 1 9 1 0 0 0 1
itch [5, itch i it itc itch BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 5 [,-].-/- 8 9 1 0 0 0 1
multiple IgE-independent multiple m mu mul mult BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 5 - 1 9 1 0 0 0 1
pathogenesis, it pathogenesis, p pa pat path BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 6 5 , 1 9 1 0 0 0 1
Fig. 1 fig. F Fi Fig Fig. BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 7 10 .-- 3 10 1 0 0 0 1
baseline IgE baseline b ba bas base BLOCKEND PAGEEND SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 7 10 //. 3 5 1 0 0 0 1
2436 2436 2436 2 24 243 2436 BLOCKSTART PAGESTART NEWFONT LOWERFONT 0 0 NOCAPS ALLDIGIT 0 0 0 0 1 0 0 0 7 0 no 0 10 1 1 0 0 1
Dermatol Ther dermatol D De Der Derm BLOCKSTART PAGEEND SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 7 2 ()():- 6 10 1 1 1 0 1
2437 2437 2437 2 24 243 2437 BLOCKSTART PAGESTART SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 1 0 0 0 7 0 no 0 1 0 1 0 0 1
Dermatol Ther dermatol D De Der Derm BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 7 0 ()():- 6 10 0 1 1 0 1
the response the t th the the BLOCKSTART PAGEIN NEWFONT HIGHERFONT 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 0 no 0 8 0 0 0 0 1
baseline IgE baseline b ba bas base BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 7 0 no 0 9 0 0 0 0 1
with a with w wi wit with BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 0 - 1 9 0 0 0 0 1
IgE levels. ige I Ig IgE IgE BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 7 0 ., 2 10 0 0 0 0 1
CSU, such csu, C CS CSU CSU, BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 7 0 ,,- 3 8 0 0 0 0 1
body that body b bo bod body BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 0 - 1 9 0 0 0 0 1
segment, reduced segment, s se seg segm BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 0 ,- 2 9 0 0 0 0 1
cebo but cebo c ce ceb cebo BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 7 0 no 0 10 0 0 0 0 1
improvements in improvements i im imp impr BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 0 []. 3 8 0 0 0 0 1
Study limitations study S St Stu Stud BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 7 0 , 1 9 0 0 0 0 1
including the including i in inc incl BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 0 - 1 9 0 0 0 0 1
atric and atric a at atr atri BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 7 0 no 0 9 0 0 0 0 1
older, and older, o ol old olde BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 0 , 1 9 0 0 0 0 1
based on based b ba bas base BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 0 , 1 9 0 0 0 0 1
may not may m ma may may BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 1 0 0 7 0 no 0 9 0 0 0 0 1
in serum in i in in in BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 7 0 . 1 9 0 0 0 0 1
24 weeks 24 2 24 24 24 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 7 0 , 1 9 0 0 0 0 1
of patient of o of of of BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 0 no 0 9 0 0 0 0 1
treatment. treatment. treatment. t tr tre trea BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 0 . 1 2 0 0 0 0 1
Fig. 2 fig. F Fi Fig Fig. BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 7 3 .() 3 8 0 0 0 0 1
and 24 and a an and and BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 3 (,),(,),(,) 11 9 0 0 0 0 1
dupilumab-or placebo-treated dupilumab-or d du dup dupi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 7 3 -- 2 8 0 0 0 0 1
serum total serum s se ser seru BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 3 //. 3 8 0 0 0 0 1
*p-values in *p-values * *p *p- *p-v BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 7 3 *--- 4 10 0 0 0 0 1
IgE. HSS7 ige. I Ig IgE IgE. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 7 3 .,- 3 9 0 0 0 0 1
globulin E, globulin g gl glo glob BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 7 3 ,, 2 9 0 0 0 0 1
squares, SE squares, s sq squ squa BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 3 ,, 2 9 0 0 0 0 1
over 7 over o ov ove over BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 3 no 0 2 0 0 0 0 1
◂ ◂ ◂ ◂ ◂ ◂ ◂ BLOCKSTART PAGEIN NEWFONT LOWERFONT 0 0 ALLCAP NODIGIT 1 0 0 0 0 0 0 0 7 5 no 0 10 0 1 0 0 1
Table 3 table T Ta Tab Tabl BLOCKSTART PAGEIN NEWFONT HIGHERFONT 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 7 5 ,, 2 10 0 0 0 0 1
and week and a an and and BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 5 no 0 1 0 0 0 0 1
HSS7 Hives hss7 H HS HSS HSS7 BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 1 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 7 6 ,,,, 4 10 0 0 0 0 1
UAS7 Urticaria uas7 U UA UAS UAS7 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 1 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 7 6 no 0 3 0 0 0 0 1
a Data a a a a a BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 1 NOCAPS NODIGIT 1 0 1 0 0 0 0 0 7 6 no 0 9 0 0 0 0 1
dupilumab arm dupilumab d du dup dupi BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 1 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 7 6 no 0 1 0 0 0 0 1
Week 12 week W We Wee Week BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 7 7 no 0 10 0 0 0 0 1
Week 24 week W We Wee Week BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 7 7 no 0 10 0 0 0 0 1
Baseline IgE baseline B Ba Bas Base BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 7 7 no 0 10 0 0 0 0 1
Placebo Placebo placebo P Pl Pla Plac BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 7 7 no 0 3 0 0 0 0 1
Dupilumab Dupilumab dupilumab D Du Dup Dupi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 7 7 no 0 4 0 0 0 0 1
Placebo Placebo placebo P Pl Pla Plac BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 7 7 no 0 3 0 0 0 0 1
Dupilumab Dupilumab dupilumab D Du Dup Dupi BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 7 7 no 0 4 0 0 0 0 1
Correlation between correlation C Co Cor Corr BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 7 8 no 0 10 0 0 0 0 1
Overall Overall overall O Ov Ove Over BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 7 8 no 0 10 0 0 0 0 1
-0.18 -0.18 -0.18 - -0 -0. -0.1 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 7 8 -. 2 7 0 0 0 0 1
0.12 0.12 0.12 0 0. 0.1 0.12 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 7 8 . 1 6 0 0 0 0 1
-0.13 -0.13 -0.13 - -0 -0. -0.1 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 7 8 -. 2 7 0 0 0 0 1
0.12 0.12 0.12 0 0. 0.1 0.12 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 7 8 . 1 6 0 0 0 0 1
< 100 < < < < < BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 1 0 0 0 0 0 0 0 7 8 / 1 10 0 0 0 0 1
-0.23 -0.23 -0.23 - -0 -0. -0.2 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 7 8 -. 2 5 0 0 0 0 1
-0.08 -0.08 -0.08 - -0 -0. -0.0 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 7 8 -. 2 5 0 0 0 0 1
0.29 0.29 0.29 0 0. 0.2 0.29 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 7 8 . 1 4 0 0 0 0 1
-0.05 -0.05 -0.05 - -0 -0. -0.0 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 7 8 -. 2 5 0 0 0 0 1
≥ 100 ≥ ≥ ≥ ≥ ≥ BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 1 0 0 0 0 0 0 0 7 9 / 1 10 0 0 0 0 1
-0.16 -0.16 -0.16 - -0 -0. -0.1 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 7 9 -. 2 5 0 0 0 0 1
0.18 0.18 0.18 0 0. 0.1 0.18 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 7 9 . 1 4 0 0 0 0 1
-0.16 -0.16 -0.16 - -0 -0. -0.1 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 7 9 -. 2 5 0 0 0 0 1
0.14 0.14 0.14 0 0. 0.1 0.14 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 7 9 . 1 4 0 0 0 0 1
Correlation between correlation C Co Cor Corr BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 7 9 no 0 10 0 0 0 0 1
Overall Overall overall O Ov Ove Over BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 7 9 no 0 10 0 0 0 0 1
-0.17 -0.17 -0.17 - -0 -0. -0.1 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 7 9 -. 2 7 0 0 0 0 1
0.11 0.11 0.11 0 0. 0.1 0.11 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 7 9 . 1 6 0 0 0 0 1
-0.13 -0.13 -0.13 - -0 -0. -0.1 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 7 9 -. 2 7 0 0 0 0 1
0.10 0.10 0.10 0 0. 0.1 0.10 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 7 9 . 1 6 0 0 0 0 1
< 100 < < < < < BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 1 0 0 0 0 0 0 0 7 9 / 1 10 0 0 0 0 1
-0.25 -0.25 -0.25 - -0 -0. -0.2 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 7 9 -. 2 5 0 0 0 0 1
-0.05 -0.05 -0.05 - -0 -0. -0.0 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 7 9 -. 2 5 0 0 0 0 1
0.29 0.29 0.29 0 0. 0.2 0.29 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 7 9 . 1 4 0 0 0 0 1
0.02 0.02 0.02 0 0. 0.0 0.02 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 7 9 . 1 4 0 0 0 0 1
≥ 100 ≥ ≥ ≥ ≥ ≥ BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 1 0 0 0 0 0 0 0 7 10 / 1 10 0 0 0 0 1
-0.13 -0.13 -0.13 - -0 -0. -0.1 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 7 10 -. 2 5 0 0 0 0 1
0.15 0.15 0.15 0 0. 0.1 0.15 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 7 10 . 1 4 0 0 0 0 1
-0.15 -0.15 -0.15 - -0 -0. -0.1 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 7 10 -. 2 5 0 0 0 0 1
0.11 0.11 0.11 0 0. 0.1 0.11 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 7 10 . 1 4 0 0 0 0 1
Correlation between correlation C Co Cor Corr BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 7 10 no 0 10 0 0 0 0 1
Overall Overall overall O Ov Ove Over BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 7 11 no 0 10 0 0 0 0 1
-0.15 -0.15 -0.15 - -0 -0. -0.1 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 7 11 -. 2 7 0 0 0 0 1
0.07 0.07 0.07 0 0. 0.0 0.07 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 7 11 . 1 6 0 0 0 0 1
-0.12 -0.12 -0.12 - -0 -0. -0.1 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 7 11 -. 2 7 0 0 0 0 1
0.08 0.08 0.08 0 0. 0.0 0.08 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 7 11 . 1 6 0 0 0 0 1
< 100 < < < < < BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 1 0 0 0 0 0 0 0 7 11 / 1 10 0 0 0 0 1
-0.25 -0.25 -0.25 - -0 -0. -0.2 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 7 11 -. 2 5 0 0 0 0 1
-0.01 -0.01 -0.01 - -0 -0. -0.0 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 7 11 -. 2 5 0 0 0 0 1
0.27 0.27 0.27 0 0. 0.2 0.27 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 7 11 . 1 4 0 0 0 0 1
0.08 0.08 0.08 0 0. 0.0 0.08 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 7 11 . 1 4 0 0 0 0 1
≥ 100 ≥ ≥ ≥ ≥ ≥ BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 1 0 0 0 0 0 0 0 7 11 / 1 10 0 0 0 0 1
-0.10 -0.10 -0.10 - -0 -0. -0.1 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 7 11 -. 2 5 0 0 0 0 1
0.10 0.10 0.10 0 0. 0.1 0.10 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 7 11 . 1 4 0 0 0 0 1
-0.12 -0.12 -0.12 - -0 -0. -0.1 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 7 11 -. 2 5 0 0 0 0 1
0.06 0.06 0.06 0 0. 0.0 0.06 BLOCKEND PAGEEND SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 7 11 . 1 4 0 0 0 0 1
2438 2438 2438 2 24 243 2438 BLOCKSTART PAGESTART NEWFONT LOWERFONT 0 0 NOCAPS ALLDIGIT 0 0 0 0 1 0 0 0 7 0 no 0 10 0 1 0 0 1
Dermatol Ther dermatol D De Der Derm BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 7 0 ()():- 6 10 0 1 1 0 1
CONCLUSIONS CONCLUSIONS conclusions C CO CON CONC BLOCKSTART PAGEIN NEWFONT HIGHERFONT 0 0 ALLCAP NODIGIT 0 0 1 0 0 0 0 0 7 0 no 0 10 0 0 0 0 1
Dupilumab was dupilumab D Du Dup Dupi BLOCKSTART PAGEIN NEWFONT LOWERFONT 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 7 0 - 1 8 0 0 0 0 1
strated significant strated s st str stra BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 7 0 no 0 9 0 0 0 0 1
and symptoms and a an and and BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 0 no 0 8 0 0 0 0 1
omalizumab naïve, omalizumab o om oma omal BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 7 0 , 1 10 0 0 0 0 1
total IgE total t to tot tota BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 0 . 1 10 0 0 0 0 1
time in time t ti tim time BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 0 -- 2 8 0 0 0 0 1
receiving dupilumab, receiving r re rec rece BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 7 0 , 1 8 0 0 0 0 1
serum total serum s se ser seru BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 0 ., 2 10 0 0 0 0 1
baseline serum baseline b ba bas base BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 7 0 no 0 10 0 0 0 0 1
Table 4 table T Ta Tab Tabl BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 8 1 no 0 10 0 1 0 0 1
IgE immunoglobulin ige I Ig IgE IgE BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 1 INITCAP NODIGIT 0 0 0 0 0 0 0 0 8 1 ,,,- 4 8 0 0 0 0 1
a Data a a a a a BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 1 NOCAPS NODIGIT 1 0 1 0 0 0 0 0 8 1 no 0 10 0 0 0 0 1
Baseline IgE baseline B Ba Bas Base BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 8 2 / 1 10 0 1 0 0 1
Baseline IgE baseline B Ba Bas Base BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 8 2 / 1 10 0 1 0 0 1
Overall Overall overall O Ov Ove Over BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 8 2 no 0 3 0 1 0 0 1
Placebo (n placebo P Pl Pla Plac BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 8 2 () 2 10 0 1 0 0 1
(n = (n ( (n (n (n BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 8 2 () 2 3 0 1 0 0 1
Placebo (n placebo P Pl Pla Plac BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 8 3 () 2 10 0 1 0 0 1
(n = (n ( (n (n (n BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 8 3 () 2 3 0 1 0 0 1
Placebo (N placebo P Pl Pla Plac BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 8 3 () 2 10 0 1 0 0 1
(N = (n ( (N (N (N BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 8 3 () 2 3 0 1 0 0 1
Participants with participants P Pa Par Part BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 8 3 no 0 10 0 0 0 0 1
TEAE, n teae, T TE TEA TEAE BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 8 3 ,() 3 5 0 0 0 0 1
21 (61.8) 21 2 21 21 21 BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 8 3 (.) 3 10 0 1 0 0 1
17 (54.8) 17 1 17 17 17 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 8 3 (.) 3 10 0 1 0 0 1
16 (51.6) 16 1 16 16 16 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 8 3 (.) 3 10 0 1 0 0 1
18 (51.4) 18 1 18 18 18 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 8 3 (.) 3 10 0 1 0 0 1
40 (58.8) 40 4 40 40 40 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 8 3 (.) 3 10 0 1 0 0 1
38 (54.3) 38 3 38 38 38 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 8 3 (.) 3 10 0 1 0 0 1
Participants with participants P Pa Par Part BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 8 4 no 0 10 0 0 0 0 1
severe TEAE, severe s se sev seve BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 4 ,() 3 8 0 0 0 0 1
3 (8.8) 3 3 3 3 3 BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 8 4 (.) 3 10 0 0 0 0 1
2 (6.5) 2 2 2 2 2 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 8 4 (.) 3 10 0 0 0 0 1
1 (3.2) 1 1 1 1 1 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 8 4 (.) 3 10 0 0 0 0 1
0 0 0 0 0 0 0 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 8 4 no 0 2 0 0 0 0 1
4 (5.9) 4 4 4 4 4 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 8 4 (.) 3 10 0 0 0 0 1
2 (2.9) 2 2 2 2 2 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 8 4 (.) 3 10 0 0 0 0 1
Participants with participants P Pa Par Part BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 8 5 no 0 10 0 0 0 0 1
treatment-emergent treatment-emergent treatment-emergent t tr tre trea BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 5 - 1 8 0 0 0 0 1
SAE, n sae, S SA SAE SAE, BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 8 5 ,() 3 5 0 0 0 0 1
4 (11.8) 4 4 4 4 4 BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 8 5 (.) 3 10 0 0 0 0 1
1 (3.2) 1 1 1 1 1 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 8 5 (.) 3 8 0 0 0 0 1
1 (3.2) 1 1 1 1 1 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 8 5 (.) 3 8 0 0 0 0 1
1 (2.9) 1 1 1 1 1 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 8 5 (.) 3 8 0 0 0 0 1
5 (7.4) 5 5 5 5 5 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 8 5 (.) 3 8 0 0 0 0 1
2 (2.9) 2 2 2 2 2 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 8 5 (.) 3 8 0 0 0 0 1
Participants with participants P Pa Par Part BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 8 5 no 0 9 0 0 0 0 1
TEAE leading teae T TE TEA TEAE BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 8 5 , 1 10 0 0 0 0 1
n (%) n n n n n BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 1 0 0 0 0 0 0 0 8 5 () 2 2 0 0 0 0 1
0 0 0 0 0 0 0 BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 8 6 no 0 2 0 0 0 0 1
0 0 0 0 0 0 0 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 8 6 no 0 2 0 0 0 0 1
1 (3.2) 1 1 1 1 1 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 8 6 (.) 3 10 0 0 0 0 1
0 0 0 0 0 0 0 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 8 6 no 0 2 0 0 0 0 1
1 (1.5) 1 1 1 1 1 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 8 6 (.) 3 10 0 0 0 0 1
0 0 0 0 0 0 0 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 8 6 no 0 2 0 0 0 0 1
Participants with participants P Pa Par Part BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 8 6 no 0 9 0 0 0 0 1
TEAE leading teae T TE TEA TEAE BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 8 6 - 1 8 0 0 0 0 1
manent study manent m ma man mane BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 8 6 no 0 10 0 0 0 0 1
discontinuation, n discontinuation, d di dis disc BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 8 6 ,() 3 10 0 0 0 0 1
1 (2.9) 1 1 1 1 1 BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 8 6 (.) 3 10 0 0 0 0 1
2 (6.5) 2 2 2 2 2 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 8 6 (.) 3 10 0 0 0 0 1
3 (9.7) 3 3 3 3 3 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 8 6 (.) 3 10 0 0 0 0 1
0 0 0 0 0 0 0 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 8 6 no 0 2 0 0 0 0 1
4 (5.9) 4 4 4 4 4 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 8 6 (.) 3 10 0 0 0 0 1
2 (2.9) 2 2 2 2 2 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 8 6 (.) 3 10 0 0 0 0 1
Participants with participants P Pa Par Part BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 8 7 ,() 3 10 0 0 0 0 1
Chronic spontaneous chronic C Ch Chr Chro BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 8 7 no 0 10 0 0 0 0 1
urticaria urticaria urticaria u ur urt urti BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 8 7 no 0 5 0 0 0 0 1
3 (8.8) 3 3 3 3 3 BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 8 7 (.) 3 10 0 0 0 0 1
1 (3.2) 1 1 1 1 1 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 8 7 (.) 3 10 0 0 0 0 1
3 (9.7) 3 3 3 3 3 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 8 7 (.) 3 10 0 0 0 0 1
1 (2.9) 1 1 1 1 1 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 8 7 (.) 3 10 0 0 0 0 1
6 (8.8) 6 6 6 6 6 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 8 7 (.) 3 10 0 0 0 0 1
3 (4.3) 3 3 3 3 3 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 8 7 (.) 3 10 0 0 0 0 1
Angioedema Angioedema angioedema A An Ang Angi BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 8 8 no 0 10 0 0 0 0 1
3 (8.8) 3 3 3 3 3 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 8 8 (.) 3 7 0 0 0 0 1
1 (3.2) 1 1 1 1 1 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 8 8 (.) 3 7 0 0 0 0 1
2 (6.5) 2 2 2 2 2 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 8 8 (.) 3 7 0 0 0 0 1
0 0 0 0 0 0 0 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 8 8 no 0 1 0 0 0 0 1
5 (7.4) 5 5 5 5 5 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 8 8 (.) 3 7 0 0 0 0 1
1 (1.4) 1 1 1 1 1 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 8 8 (.) 3 7 0 0 0 0 1
Injection-site reaction injection-site I In Inj Inje BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 8 8 -(.) 4 10 0 0 0 0 1
3 (9.7) 3 3 3 3 3 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 8 8 (.) 3 2 0 0 0 0 1
0 0 0 0 0 0 0 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 8 8 no 0 0 0 0 0 0 1
0 0 0 0 0 0 0 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 8 8 no 0 0 0 0 0 0 1
2 (2.9) 2 2 2 2 2 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 8 8 (.) 3 2 0 0 0 0 1
4 (5.7) 4 4 4 4 4 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 8 8 (.) 3 2 0 0 0 0 1
Injection-site erythema injection-site I In Inj Inje BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 8 9 -(.) 4 10 0 0 0 0 1
2 (6.5) 2 2 2 2 2 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 8 9 (.) 3 2 0 0 0 0 1
0 0 0 0 0 0 0 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 8 9 no 0 0 0 0 0 0 1
0 0 0 0 0 0 0 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 8 9 no 0 0 0 0 0 0 1
4 (5.9) 4 4 4 4 4 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 8 9 (.) 3 2 0 0 0 0 1
3 (4.3) 3 3 3 3 3 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 8 9 (.) 3 2 0 0 0 0 1
Headache Headache headache H He Hea Head BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 8 9 no 0 10 0 0 0 0 1
2 (5.9) 2 2 2 2 2 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 8 9 (.) 3 8 0 0 0 0 1
0 0 0 0 0 0 0 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 8 9 no 0 2 0 0 0 0 1
0 0 0 0 0 0 0 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 8 9 no 0 2 0 0 0 0 1
2 (5.7) 2 2 2 2 2 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 8 9 (.) 3 8 0 0 0 0 1
3 (4.4) 3 3 3 3 3 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 8 9 (.) 3 8 0 0 0 0 1
2 (2.9) 2 2 2 2 2 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 8 9 (.) 3 8 0 0 0 0 1
Nasopharyngitis Nasopharyngitis nasopharyngitis N Na Nas Naso BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 8 10 no 0 10 0 0 0 0 1
3 (8.8) 3 3 3 3 3 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 8 10 (.) 3 5 0 0 0 0 1
0 0 0 0 0 0 0 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 8 10 no 0 1 0 0 0 0 1
0 0 0 0 0 0 0 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 8 10 no 0 1 0 0 0 0 1
1 (2.9) 1 1 1 1 1 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 8 10 (.) 3 5 0 0 0 0 1
3 (4.4) 3 3 3 3 3 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 8 10 (.) 3 5 0 0 0 0 1
1 (1.4) 1 1 1 1 1 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 8 10 (.) 3 5 0 0 0 0 1
Abdominal pain abdominal A Ab Abd Abdo BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 8 10 (.) 3 10 0 0 0 0 1
0 0 0 0 0 0 0 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 8 10 no 0 0 0 0 0 0 1
0 0 0 0 0 0 0 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 8 10 no 0 0 0 0 0 0 1
0 0 0 0 0 0 0 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 8 10 no 0 0 0 0 0 0 1
2 (2.9) 2 2 2 2 2 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 8 10 (.) 3 2 0 0 0 0 1
0 0 0 0 0 0 0 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 8 10 no 0 0 0 0 0 0 1
Back pain back B Ba Bac Back BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 1 1 0 0 0 0 0 8 11 no 0 5 0 0 0 0 1
0 0 0 0 0 0 0 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 8 11 no 0 1 0 0 0 0 1
0 0 0 0 0 0 0 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 8 11 no 0 1 0 0 0 0 1
3 (9.7) 3 3 3 3 3 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 8 11 (.) 3 4 0 0 0 0 1
0 0 0 0 0 0 0 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 8 11 no 0 1 0 0 0 0 1
3 (4.4) 3 3 3 3 3 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 8 11 (.) 3 4 0 0 0 0 1
0 0 0 0 0 0 0 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 8 11 no 0 1 0 0 0 0 1
Dermatitis contact dermatitis D De Der Derm BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 8 11 no 0 10 0 0 0 0 1
0 0 0 0 0 0 0 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 8 11 no 0 1 0 0 0 0 1
0 0 0 0 0 0 0 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 8 11 no 0 1 0 0 0 0 1
3 (9.7) 3 3 3 3 3 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 8 11 (.) 3 4 0 0 0 0 1
1 (2.9) 1 1 1 1 1 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 8 11 (.) 3 4 0 0 0 0 1
3 (4.4) 3 3 3 3 3 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 8 11 (.) 3 4 0 0 0 0 1
1 (1.4) 1 1 1 1 1 BLOCKEND PAGEEND SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 8 11 (.) 3 4 0 0 0 0 1
2439 2439 2439 2 24 243 2439 BLOCKSTART PAGESTART NEWFONT LOWERFONT 0 0 NOCAPS ALLDIGIT 0 0 0 0 1 0 0 0 8 0 no 0 1 0 1 0 0 1
Dermatol Ther dermatol D De Der Derm BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 8 0 ()():- 6 10 0 1 1 0 1
as a as a as as as BLOCKSTART PAGEIN NEWFONT HIGHERFONT 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 0 no 0 10 0 1 0 0 1
in patients in i in in in BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 8 0 . 1 5 0 1 0 0 1
ACKNOWLEDGEMENTS ACKNOWLEDGEMENTS acknowledgements A AC ACK ACKN BLOCKSTART PAGEIN NEWFONT HIGHERFONT 0 0 ALLCAP NODIGIT 0 0 1 0 0 0 0 0 8 0 no 0 10 0 1 0 0 1
We thank we W We We We BLOCKSTART PAGEIN NEWFONT LOWERFONT 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 8 0 . 1 10 0 0 0 0 1
Medical Writing/Editorial medical M Me Med Medi BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 1 1 INITCAP NODIGIT 0 0 1 0 0 0 0 0 8 0 /.- 3 8 0 0 0 0 1
ical writing/editorial ical i ic ica ical BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 1 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 8 0 / 1 10 0 0 0 0 1
Moataz Badawi, moataz M Mo Moa Moat BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 1 INITCAP NODIGIT 0 0 0 0 0 0 0 0 8 0 ,,, 3 8 0 0 0 0 1
was funded was w wa was was BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 1 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 0 - 1 8 0 0 0 0 1
ceuticals Inc., ceuticals c ce ceu ceut BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 1 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 8 0 ., 2 10 0 0 0 0 1
n Pract n n n n n BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 1 1 NOCAPS NODIGIT 1 0 0 0 0 0 0 0 8 0 . 1 5 0 0 0 0 1
Author Contributions. author A Au Aut Auth BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 1 1 INITCAP NODIGIT 0 0 1 0 0 0 0 0 8 1 .- 2 7 0 0 0 0 1
tion: Marcus tion: t ti tio tion BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 1 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 8 1 :,., 4 9 0 0 0 0 1
S. Saini, s. S S. S. S. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 1 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 8 1 .,-,, 5 9 0 0 0 0 1
Jennifer Maloney, jennifer J Je Jen Jenn BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 1 INITCAP NODIGIT 0 1 0 0 0 0 0 0 8 1 ,,, 3 9 0 0 0 0 1
Melanie Makhija. melanie M Me Mel Mela BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 1 INITCAP NODIGIT 0 1 0 0 0 0 0 0 8 1 .:, 3 9 0 0 0 0 1
Jennifer Maloney, jennifer J Je Jen Jenn BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 1 INITCAP NODIGIT 0 1 0 0 0 0 0 0 8 1 ,,, 3 9 0 0 0 0 1
Melanie Makhija. melanie M Me Mel Mela BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 1 INITCAP NODIGIT 0 1 0 0 0 0 0 0 8 1 .: 2 8 0 0 0 0 1
Laws, Jennifer laws, L La Law Laws BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 1 INITCAP NODIGIT 0 0 1 0 0 0 0 0 8 1 ,,, 3 9 0 0 0 0 1
Radin, Melanie radin, R Ra Rad Radi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 1 INITCAP NODIGIT 0 0 0 0 0 0 0 0 8 1 ,.: 3 9 0 0 0 0 1
Maurer, Thomas maurer, M Ma Mau Maur BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 1 INITCAP NODIGIT 0 0 0 0 0 0 0 0 8 1 ,.,..- 6 10 0 0 0 0 1
ing review ing i in ing ing BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 1 NOCAPS NODIGIT 0 1 0 0 0 0 0 0 8 1 :, 2 9 0 0 0 0 1
B. Casale, b. B B. B. B. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 1 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 8 1 .,.,-, 6 9 0 0 0 0 1
Elizabeth Laws, elizabeth E El Eli Eliz BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 1 INITCAP NODIGIT 0 1 0 0 0 0 0 0 8 1 ,, 2 8 0 0 0 0 1
Bauer, Allen bauer, B Ba Bau Baue BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 1 1 INITCAP NODIGIT 0 0 0 0 0 0 0 0 8 1 ,,. 3 7 0 0 0 0 1
Funding. LIBERTY-CSU funding. F Fu Fun Fund BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 1 1 INITCAP NODIGIT 0 0 1 0 0 0 0 0 8 3 .- 2 7 0 0 0 0 1
was sponsored was w wa was was BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 1 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 3 - 1 8 0 0 0 0 1
maceuticals Inc., maceuticals m ma mac mace BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 1 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 8 3 .,.: 4 10 0 0 0 0 1
NCT04180488. The nct04180488. N NC NCT NCT0 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 1 ALLCAP CONTAINSDIGITS 0 0 0 0 1 0 0 0 8 3 .' 2 9 0 0 0 0 1
was also was w wa was was BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 1 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 3 - 1 9 0 0 0 0 1
maceuticals Inc. maceuticals m ma mac mace BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 1 1 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 8 3 . 1 3 0 0 0 0 1
Data Availability. data D Da Dat Data BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 1 1 INITCAP NODIGIT 0 0 1 0 0 0 0 0 8 4 . 1 8 0 0 0 0 1
may request may m ma may may BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 1 NOCAPS NODIGIT 0 1 1 0 0 1 0 0 8 4 (- 2 9 0 0 0 0 1
ing the ing i in ing ing BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 1 NOCAPS NODIGIT 0 1 0 0 0 0 0 0 8 4 , 1 10 0 0 0 0 1
any amendments, any a an any any BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 1 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 4 ,, 2 8 0 0 0 0 1
statistical analysis statistical s st sta stat BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 1 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 4 )- 2 9 0 0 0 0 1
ods and ods o od ods ods BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 1 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 8 4 . 1 9 0 0 0 0 1
Individual de-identified individual I In Ind Indi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 1 INITCAP NODIGIT 0 0 1 0 0 0 0 0 8 4 - 1 9 0 0 0 0 1
be made be b be be be BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 1 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 4 no 0 9 0 0 0 0 1
approved by approved a ap app appr BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 1 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 4 - 1 9 0 0 0 0 1
ticipant consent ticipant t ti tic tici BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 1 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 8 4 no 0 9 0 0 0 0 1
likelihood of likelihood l li lik like BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 1 1 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 4 . 1 8 0 0 0 0 1
Declarations Declarations declarations D De Dec Decl BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 1 1 INITCAP NODIGIT 0 0 1 0 0 0 0 0 9 5 no 0 10 0 1 0 0 1
Conflict of conflict C Co Con Conf BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 1 1 INITCAP NODIGIT 0 0 1 0 0 0 0 0 9 5 . 1 8 0 0 0 0 1
speaker and/or speaker s sp spe spea BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 1 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 9 5 // 2 9 0 0 0 0 1
research support research r re res rese BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 1 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 9 5 ,,- 3 9 0 0 0 0 1
tech, Almirall, tech, t te tec tech BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 1 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 9 5 ,,,,, 5 8 0 0 0 0 1
AstraZeneca, Celldex astrazeneca, A As Ast Astr BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 1 INITCAP NODIGIT 0 0 0 0 0 0 0 0 9 5 ,,, 3 9 0 0 0 0 1
Clinuvel Pharmaceuticals, clinuvel C Cl Cli Clin BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 1 INITCAP NODIGIT 0 0 0 0 0 0 0 0 9 5 ,- 2 9 0 0 0 0 1
cals, Evommune, cals, c ca cal cals BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 1 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 9 5 ,,,, 4 9 0 0 0 0 1
Incyte, Jasper incyte, I In Inc Incy BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 1 INITCAP NODIGIT 0 0 0 0 0 0 0 0 9 5 ,,, 3 9 0 0 0 0 1
Kyowa Kirin, kyowa K Ky Kyo Kyow BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 1 INITCAP NODIGIT 0 0 0 0 0 0 0 0 9 5 ,,,,- 5 9 0 0 0 0 1
subishi Tanabe subishi s su sub subi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 1 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 9 5 ,, 2 9 0 0 0 0 1
Noucor, Novartis, noucor, N No Nou Nouc BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 1 INITCAP NODIGIT 0 0 0 0 0 0 0 0 9 5 ,,, 3 8 0 0 0 0 1
Medicine, Sanofi-Regeneron medicine, M Me Med Medi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 1 INITCAP NODIGIT 0 0 1 0 0 0 0 0 9 5 ,- 2 8 0 0 0 0 1
Inc., Santa inc., I In Inc Inc. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 1 INITCAP NODIGIT 0 0 0 0 0 0 0 0 9 5 .,,,, 5 9 0 0 0 0 1
Harmonic Bio, harmonic H Ha Har Harm BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 1 INITCAP NODIGIT 0 0 1 0 0 0 0 0 9 5 ,,, 3 9 0 0 0 0 1
Corporation, and corporation, C Co Cor Corp BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 1 INITCAP NODIGIT 0 0 1 0 0 0 0 0 9 5 ,.. 3 8 0 0 0 0 1
reports research reports r re rep repo BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 1 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 9 5 - 1 8 0 0 0 0 1
peutics, Alladapt peutics, p pe peu peut BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 1 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 9 5 ,, 2 9 0 0 0 0 1
Therapeutics, ARS therapeutics, T Th The Ther BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 1 INITCAP NODIGIT 0 0 0 0 0 0 0 0 9 5 ,,,, 4 8 0 0 0 0 1
PCORI, Pfizer, pcori, P PC PCO PCOR BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 1 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 9 5 ,,., 4 9 0 0 0 0 1
and Sanofi; and a an and and BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 1 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 5 ;- 2 9 0 0 0 0 1
peutics, ARS peutics, p pe peu peut BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 1 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 9 5 ,,,, 4 9 0 0 0 0 1
Novartis, and novartis, N No Nov Nova BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 1 INITCAP NODIGIT 0 0 0 0 0 0 0 0 9 5 ,.; 3 9 0 0 0 0 1
is on is i is is is BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 1 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 5 no 0 8 0 0 0 0 1
Sanofi; and sanofi; S Sa San Sano BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 1 INITCAP NODIGIT 0 0 0 0 0 0 0 0 9 5 ; 1 10 0 0 0 0 1
Allergy Research allergy A Al All Alle BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 1 INITCAP NODIGIT 0 0 1 0 0 0 0 0 9 5 ().. 4 9 0 0 0 0 1
Saini reports saini S Sa Sai Sain BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 1 INITCAP NODIGIT 0 1 0 0 0 0 0 0 9 5 // 2 9 0 0 0 0 1
clinical trial clinical c cl cli clin BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 1 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 5 ,,- 3 9 0 0 0 0 1
ent Pharmaceuticals, ent e en ent ent BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 1 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 9 5 ,,,, 4 8 0 0 0 0 1
Regeneron Pharmaceuticals regeneron R Re Reg Rege BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 1 INITCAP NODIGIT 0 0 0 0 0 0 0 0 9 5 ., 2 8 0 0 0 0 1
as a as a as as as BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 1 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 5 - 1 9 0 0 0 0 1
kos, Aquestive, kos, k ko kos kos, BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 1 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 9 5 ,,,- 4 9 0 0 0 0 1
cals, Innate cals, c ca cal cals BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 1 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 9 5 ,,, 3 9 0 0 0 0 1
Novartis, Regeneron novartis, N No Nov Nova BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 1 INITCAP NODIGIT 0 0 0 0 0 0 0 0 9 5 ,., 3 9 0 0 0 0 1
Sanofi. Moshe sanofi. S Sa San Sano BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 1 INITCAP NODIGIT 0 0 0 0 0 0 0 0 9 5 .- 2 8 0 0 0 0 1
with Bausch with w wi wit with BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 1 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 5 ,, 2 9 0 0 0 0 1
Miravo, Novartis, miravo, M Mi Mir Mira BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 1 INITCAP NODIGIT 0 0 0 0 0 0 0 0 9 5 ,,,. 4 10 0 0 0 0 1
Elizabeth Laws, elizabeth E El Eli Eliz BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 1 INITCAP NODIGIT 0 1 0 0 0 0 0 0 9 5 ,, 2 8 0 0 0 0 1
Makhija are makhija M Ma Mak Makh BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 1 INITCAP NODIGIT 0 0 0 0 0 0 0 0 9 5 no 0 9 0 0 0 0 1
stock and/or stock s st sto stoc BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 1 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 9 5 /.- 3 9 0 0 0 0 1
nifer Maloney nifer n ni nif nife BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 1 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 9 5 no 0 8 0 0 0 0 1
and shareholders and a an and and BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 1 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 5 no 0 9 0 0 0 0 1
Inc. Inc. inc. I In Inc Inc. BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 1 1 INITCAP NODIGIT 0 0 0 0 0 0 0 0 9 5 . 1 1 0 0 0 0 1
Ethical Approval. ethical E Et Eth Ethi BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 1 1 INITCAP NODIGIT 0 0 1 0 0 0 0 0 9 11 . 1 8 0 0 0 0 1
in accordance in i in in in BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 1 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 9 11 , 1 9 0 0 0 0 1
the International the t th the the BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 1 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 11 no 0 9 0 0 0 0 1
Good Clinical good G Go Goo Good BLOCKEND PAGEEND SAMEFONT SAMEFONTSIZE 1 1 INITCAP NODIGIT 0 1 1 0 0 0 0 0 9 11 , 1 10 0 0 0 0 1
2440 2440 2440 2 24 244 2440 BLOCKSTART PAGESTART NEWFONT LOWERFONT 0 0 NOCAPS ALLDIGIT 0 0 0 0 1 0 0 0 9 0 no 0 10 0 1 0 0 1
Dermatol Ther dermatol D De Der Derm BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 9 0 ()():- 6 10 0 1 1 0 1
regulatory requirements. regulatory r re reg regu BLOCKSTART PAGEIN NEWFONT HIGHERFONT 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 0 . 1 9 0 0 0 0 1
parents/guardians provided parents/guardians p pa par pare BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 9 0 / 1 8 0 0 0 0 1
consent before consent c co con cons BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 0 .- 2 9 0 0 0 0 1
atric patients atric a at atr atri BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 9 0 no 0 9 0 0 0 0 1
Ethics Committee ethics E Et Eth Ethi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 9 0 ( 1 9 0 0 0 0 1
[IRB]/Independent Ethics [irb]/independent [ [I [IR [IRB BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 9 0 []/)- 5 9 0 0 0 0 1
standard practice standard s st sta stan BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 0 no 0 10 0 0 0 0 1
participating center. participating p pa par part BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 0 . 1 4 0 0 0 0 1
Open Access. open O Op Ope Open BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 1 1 INITCAP NODIGIT 0 0 1 0 0 0 0 0 9 0 . 1 8 0 0 0 0 1
Creative Commons creative C Cr Cre Crea BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 1 INITCAP NODIGIT 0 0 1 0 0 0 0 0 9 0 - 1 7 0 0 0 0 1
4.0 International 4.0 4 4. 4.0 4.0 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 1 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 9 0 ., 2 8 0 0 0 0 1
non-commercial use, non-commercial n no non non- BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 1 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 9 0 -,,,- 5 8 0 0 0 0 1
bution and bution b bu but buti BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 1 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 9 0 - 1 8 0 0 0 0 1
mat, as mat, m ma mat mat, BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 1 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 0 , 1 9 0 0 0 0 1
original author(s) original o or ori orig BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 1 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 0 (), 3 9 0 0 0 0 1
to the to t to to to BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 1 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 0 , 1 8 0 0 0 0 1
if changes if i if if if BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 1 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 0 . 1 8 0 0 0 0 1
party material party p pa par part BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 1 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 0 no 0 9 0 0 0 0 1
article's Creative article's a ar art arti BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 1 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 9 0 ',- 3 8 0 0 0 0 1
cated otherwise cated c ca cat cate BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 1 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 9 0 . 1 9 0 0 0 0 1
If material if I If If If BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 1 INITCAP NODIGIT 0 0 1 0 0 0 0 0 9 0 '- 2 9 0 0 0 0 1
tive Commons tive t ti tiv tive BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 1 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 9 0 no 0 8 0 0 0 0 1
not permitted not n no not not BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 1 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 0 no 0 8 0 0 0 0 1
the permitted the t th the the BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 1 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 0 ,- 2 8 0 0 0 0 1
mission directly mission m mi mis miss BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 1 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 0 . 1 8 0 0 0 0 1
view a view v vi vie view BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 1 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 0 ,:// 4 10 0 0 0 0 1
mmons. org/ mmons. m mm mmo mmon BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 1 1 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 9 0 .//-/./. 8 6 0 0 0 0 1
REFERENCES REFERENCES references R RE REF REFE BLOCKSTART PAGEIN NEWFONT HIGHERFONT 0 0 ALLCAP NODIGIT 0 0 1 0 0 0 0 0 9 3 no 0 10 0 0 0 0 1
1. Gonçalo 1. 1 1. 1. 1. BLOCKSTART PAGEIN NEWFONT LOWERFONT 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 9 3 .,-,-, 6 7 0 0 0 0 1
et al. et e et et et BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 9 3 . 1 8 0 0 0 0 1
for the for f fo for for BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 3 .. 2 8 0 0 0 0 1
2021;184(2):226-36. https:// 2021;184(2):226-36. 2 20 202 2021 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 1 0 0 0 9 3 ;():-.://././. 14 10 0 0 0 0 1
19561. 19561. 19561. 1 19 195 1956 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 1 0 0 0 9 3 . 1 1 0 0 0 0 1
2. Maurer 2. 2 2. 2. 2. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 9 3 .,,,. 5 8 0 0 0 0 1
burden of burden b bu bur burd BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 9 3 - 1 8 0 0 0 0 1
stantial: real-world stantial: s st sta stan BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 9 3 :--. 4 8 0 0 0 0 1
Allergy. 2017;72(12):2005-16. allergy. A Al All Alle BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 9 3 .;():-.://./. 13 10 0 0 0 0 1
1111/ all. 1111/ 1 11 111 1111 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 1 0 0 0 9 3 /.. 3 3 0 0 0 0 1
3. Maurer 3. 3 3. 3. 3. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 9 4 .,,., 5 10 0 0 0 0 1
pathogenesis, diagnostic pathogenesis, p pa pat path BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 9 4 ,,- 3 8 0 0 0 0 1
ment of ment m me men ment BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 9 4 :.- 3 8 0 0 0 0 1
col. 2022;268:117-33. col. c co col col. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 9 4 .;:-.://././ 12 9 0 0 0 0 1
164_ 2021_ 164_ 1 16 164 164_ BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 9 4 . 1 2 0 0 0 0 1
4. Zuberbier 4. 4 4. 4. 4. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 9 4 .,,,. 5 10 0 1 0 0 1
The international the T Th The The BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 9 4 /// 3 8 0 1 0 0 1
APAAACI guideline apaaaci A AP APA APAA BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 9 4 ,- 2 9 0 1 0 0 1
tion, diagnosis, tion, t ti tio tion BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 9 4 ,,. 3 8 0 1 0 0 1
Allergy. 2022;77(3):734-66. allergy. A Al All Alle BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 10 5 .;():-.://./. 13 10 0 1 0 0 1
1111/ all. 1111/ 1 11 111 1111 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 1 0 0 0 10 5 /.. 3 3 0 1 0 0 1
5. Church 5. 5 5. 5. 5. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 10 5 .,,,. 5 9 0 1 0 0 1
and relevance and a an and and BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 10 5 . 1 9 0 1 0 0 1
Rev. 2018;282(1):232-47. rev. R Re Rev Rev. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 10 5 .;():-.://././ 14 10 0 1 0 0 1
imr. 12632. imr. i im imr imr. BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 10 5 .. 2 2 0 1 0 0 1
6. Kolkhir 6. 6 6. 6. 6. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 10 6 .,,,,- 6 10 0 0 0 0 1
rer M. rer r re rer rer BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 10 6 .[- 3 10 0 0 0 0 1
lished correction lished l li lis lish BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 10 6 no 0 9 0 0 0 0 1
Immunol. 2022;128:234]. immunol. I Im Imm Immu BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 10 6 .;:]. 5 8 0 0 0 0 1
Immunol. 2020;124(1):2-12. immunol. I Im Imm Immu BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 10 6 .;():-.://./. 13 10 0 0 0 0 1
1016/j. anai. 1016/j. 1 10 101 1016 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS CONTAINSDIGITS 0 0 0 0 1 0 0 0 10 6 /..... 6 5 0 0 0 0 1
7. Gowthaman 7. 7 7. 7. 7. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 10 6 .,,,.- 6 10 0 0 0 0 1
lar helper lar l la lar lar BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 10 6 -. 2 9 0 0 0 0 1
Opin Immunol. opin O Op Opi Opin BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 10 6 .;:-.://./. 11 9 0 0 0 0 1
1016/j. coi. 1016/j. 1 10 101 1016 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS CONTAINSDIGITS 0 0 0 0 1 0 0 0 10 6 /..... 6 5 0 0 0 0 1
8. Altrichter 8. 8 8. 8. 8. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 10 7 .,,,. 5 10 0 0 0 0 1
marker for marker m ma mar mark BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 10 7 . 1 9 0 0 0 0 1
Asthma Immunol asthma A As Ast Asth BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 10 7 .;():-.:// 10 8 0 0 0 0 1
doi. org/ doi. d do doi doi. BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 10 7 ././..... 9 7 0 0 0 0 1
9. Chuang 9. 9 9. 9. 9. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 10 8 .-,-,-,-. 9 8 0 0 0 0 1
Association between association A As Ass Asso BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 10 8 no 0 8 0 0 0 0 1
clinical response clinical c cl cli clin BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 10 8 no 0 8 0 0 0 0 1
spontaneous urticaria: spontaneous s sp spo spon BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 10 8 : 1 8 0 0 0 0 1
meta-analysis. J meta-analysis. m me met meta BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 10 8 -.. 3 8 0 0 0 0 1
2023;11(8):2382-89.e3. https:// 2023;11(8):2382-89.e3. 2 20 202 2023 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS CONTAINSDIGITS 0 0 0 0 1 0 0 0 10 8 ;():-..://././. 15 10 0 0 0 0 1
jaip. 2023. jaip. j ja jai jaip BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 10 8 .... 4 3 0 0 0 0 1
10. Kaplan 10. 1 10 10. 10. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 10 9 .,-,.- 6 9 0 0 0 0 1
nisms of nisms n ni nis nism BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 10 9 - 1 9 0 0 0 0 1
izumab in izumab i iz izu izum BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 10 9 .. 2 9 0 0 0 0 1
2017;72(4):519-33. https:// 2017;72(4):519-33. 2 20 201 2017 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 1 0 0 0 10 9 ;():-.://././. 14 10 0 0 0 0 1
13083. 13083. 13083. 1 13 130 1308 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 1 0 0 0 10 9 . 1 1 0 0 0 0 1
11. Kaplan 11. 1 11 11. 11. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 10 9 ..:- 4 10 0 0 0 0 1
genesis and genesis g ge gen gene BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 0 0 0 0 0 0 10 9 . 1 8 0 0 0 0 1
Asthma Immunol asthma A As Ast Asth BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 10 9 .;():-.:// 10 9 0 0 0 0 1
doi. org/ doi. d do doi doi. BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 10 9 ././..... 9 8 0 0 0 0 1
12. Macdonald 12. 1 12 12. 12. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 10 10 .,,,.- 6 9 0 0 0 0 1
cise and cise c ci cis cise BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 10 10 no 0 9 0 0 0 0 1
mouse immunoglobulin mouse m mo mou mous BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 10 10 . 1 9 0 0 0 0 1
USA. 2014;111(14):5147-52. usa. U US USA USA. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 10 10 .;():-.://./. 13 10 0 0 0 0 1
1073/ pnas. 1073/ 1 10 107 1073 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 1 0 0 0 10 10 /.. 3 5 0 0 0 0 1
13. Murphy 13. 1 13 13. 13. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 10 10 .,,,. 5 10 0 0 0 0 1
with megabase with w wi wit with BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 10 10 - 1 7 0 0 0 0 1
noglobulin genes noglobulin n no nog nogl BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 10 10 - 1 8 0 0 0 0 1
ciently as ciently c ci cie cien BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 10 10 .. 2 9 0 0 0 0 1
2014;111(14):5153-8. https:// 2014;111(14):5153-8. 2 20 201 2014 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 1 0 0 0 10 10 ;():-.://././ 13 9 0 0 0 0 1
pnas. 13240 pnas. p pn pna pnas BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 10 10 .. 2 3 0 0 0 0 1
14. Harb 14. 1 14 14. 14. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 10 11 .,.. 4 9 0 0 0 0 1
Clin Exp clin C Cl Cli Clin BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 10 11 .;():-.://./ 12 10 0 0 0 0 1
10. 1111/ 10. 1 10 10. 10. BLOCKEND PAGEEND SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 10 11 ./.. 4 4 0 0 0 0 1
2441 2441 2441 2 24 244 2441 BLOCKSTART PAGESTART NEWFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 1 0 0 0 10 0 no 0 1 0 1 0 0 1
Dermatol Ther dermatol D De Der Derm BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 10 0 ()():- 6 10 0 1 1 0 1
15. Le 15. 1 15 15. 15. BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 10 0 .',,,. 6 10 0 1 0 0 1
blockade of blockade b bl blo bloc BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 10 0 --, 3 8 0 1 0 0 1
IL-4Rα antibody, il-4rα I IL IL- IL-4 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 10 0 -, 2 9 0 1 0 0 1
type 2 type t ty typ type BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 10 0 ..;():- 7 8 0 1 0 0 1
204. https:// 204. 2 20 204 204. BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 10 0 .://././.. 10 8 0 1 0 0 1
16. Maurer 16. 1 16 16. 16. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 10 0 .,,,. 5 10 0 0 0 0 1
patients with patients p pa pat pati BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 10 0 (- 2 8 0 0 0 0 1
ERTY-CSU CUPID): erty-csu E ER ERT ERTY BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 10 0 -):,-, 6 8 0 0 0 0 1
placebo-controlled, phase placebo-controlled, p pl pla plac BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 10 0 -,. 3 9 0 0 0 0 1
Immunol. 2024;S0091-6749(24):00196-9. immunol. I Im Imm Immu BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 10 0 .;-():-.:// 11 8 0 0 0 0 1
doi. org/ doi. d do doi doi. BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 10 0 ././..... 9 7 0 0 0 0 1
17. Bachert 17. 1 17 17. 17. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 10 1 .,,,. 5 10 0 0 0 0 1
and safety and a an and and BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 10 1 no 0 9 0 0 0 0 1
chronic rhinosinusitis chronic c ch chr chro BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 10 1 ( 1 9 0 0 0 0 1
NP SINUS-24 np N NP NP NP BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 10 1 --): 4 8 0 0 0 0 1
from two from f fr fro from BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 10 1 ,,-, 4 9 0 0 0 0 1
placebo-controlled, parallel-group placebo-controlled, p pl pla plac BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 10 1 -,-. 4 9 0 0 0 0 1
Lancet. 2019;394(10209):1638-50. lancet. L La Lan Lanc BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 10 1 .;():-.://./ 12 9 0 0 0 0 1
10. 1016/ 10. 1 10 10. 10. BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 10 1 ./-()-. 7 6 0 0 0 0 1
18. Castro 18. 1 18 18. 18. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 10 2 .,,,. 5 10 0 0 0 0 1
efficacy and efficacy e ef eff effi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 10 2 --- 3 9 0 0 0 0 1
trolled asthma. trolled t tr tro trol BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 10 2 ..;():- 7 9 0 0 0 0 1
96. https:// 96. 9 96 96. 96. BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 10 2 .://././. 9 9 0 0 0 0 1
19. Corren 19. 1 19 19. 19. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 10 2 .,,,.-- 7 10 0 0 0 0 1
cutaneous allergy cutaneous c cu cut cuta BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 10 2 no 0 8 0 0 0 0 1
are well are a ar are are BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 10 2 : 1 9 0 0 0 0 1
trial. J trial. t tr tri tria BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 10 2 ..;:-.:// 9 9 0 0 0 0 1
doi. org/ doi. d do doi doi. BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 10 2 ././.. 6 6 0 0 0 0 1
20. Paller 20. 2 20 20. 20. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 11 3 .,,,. 5 10 0 0 0 0 1
2, open-label 2, 2 2, 2, 2, BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 11 3 ,-- 3 8 0 0 0 0 1
children aged children c ch chi chil BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 11 3 no 0 8 0 0 0 0 1
uncontrolled atopic uncontrolled u un unc unco BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 11 3 :, 2 8 0 0 0 0 1
safety and safety s sa saf safe BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 11 3 .. 2 9 0 0 0 0 1
2021;35(2):464-75. https:// 2021;35(2):464-75. 2 20 202 2021 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 1 0 0 0 11 3 ;():-.://././. 14 9 0 0 0 0 1
16928. 16928. 16928. 1 16 169 1692 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 1 0 0 0 11 3 . 1 1 0 0 0 0 1
21. McLeod 21. 2 21 21. 21. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 11 4 .,,.- 5 9 0 0 0 0 1
tion and tion t ti tio tion BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 11 4 --.. 4 8 0 0 0 0 1
2015;75(1):57-61. https:// 2015;75(1):57-61. 2 20 201 2015 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 1 0 0 0 11 4 ;():-.://././.. 15 10 0 0 0 0 1
2015. 05. 2015. 2 20 201 2015 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 1 0 0 0 11 4 ... 3 2 0 0 0 0 1
22. Oetjen 22. 2 22 22. 22. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 11 4 .,,,. 5 9 0 0 0 0 1
co-opt classical co-opt c co co- co-o BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 11 4 - 1 8 0 0 0 0 1
mediate chronic mediate m me med medi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 11 4 ..;():-. 8 8 0 0 0 0 1
e13. https:// e13. e e1 e13 e13. BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS CONTAINSDIGITS 0 0 0 0 0 0 0 0 11 4 .://././..... 13 10 0 0 0 0 1
23. Giménez-Arnau 23. 2 23 23. 23. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 11 5 .-,,, 5 7 0 0 0 0 1
et al. et e et et et BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 11 5 . 1 8 0 0 0 0 1
urticaria: the urticaria: u ur urt urti BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 11 5 :. 2 10 0 0 0 0 1
Immunol Pract. immunol I Im Imm Immu BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 11 5 .;():-.://. 11 8 0 0 0 0 1
org/ 10. org/ o or org org/ BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 11 5 /./..... 8 6 0 0 0 0 1
24. Ingrasci 24. 2 24 24. 24. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 11 5 .,,,.- 6 9 0 0 0 0 1
ritogenic role ritogenic r ri rit rito BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 11 5 no 0 8 0 0 0 0 1
diseases associated diseases d di dis dise BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 11 5 .- 2 9 0 0 0 0 1
tol. 2021;30(9):1208-17. tol. t to tol tol. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 11 5 .;():-.://././ 14 10 0 0 0 0 1
exd. 14401. exd. e ex exd exd. BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 11 5 .. 2 2 0 0 0 0 1
25. Kolkhir 25. 2 25 25. 25. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 11 6 .,-,, 5 8 0 1 0 0 1
Peter J, peter P Pe Pet Pete BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 1 0 0 0 0 0 0 11 6 ,,.. 4 9 0 1 0 0 1
Primers. 2022;8(1):61. primers. P Pr Pri Prim BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 11 6 .;():.://././ 13 10 0 1 0 0 1
s41572-022-00389-z. s41572-022-00389-z. s41572-022-00389-z. s s4 s41 s415 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS CONTAINSDIGITS 0 0 0 0 1 0 0 0 11 6 ---. 4 3 0 1 0 0 1
26. Dekkers 26. 2 26 26. 26. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 11 6 .,,,- 5 9 0 0 0 0 1
ker DS, ker k ke ker ker BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 11 6 ,-,. 4 9 0 0 0 0 1
in patients in i in in in BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 11 6 no 0 10 0 0 0 0 1
during treatment during d du dur duri BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 11 6 no 0 8 0 0 0 0 1
dose interval. dose d do dos dose BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 11 6 ..;():- 7 9 0 0 0 0 1
5. https:// 5. 5 5. 5. 5. BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 11 6 .://././.. 10 8 0 0 0 0 1
27. Siegfried 27. 2 27 27. 27. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 11 7 .,,,. 5 9 0 0 0 0 1
Dupilumab treatment dupilumab D Du Dup Dupi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 11 7 no 0 8 0 0 0 0 1
in patients in i in in in BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 11 7 - 1 8 0 0 0 0 1
to-severe atopic to-severe t to to- to-s BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 11 7 -.. 3 9 0 0 0 0 1
2023;63(3): 103434. 2023;63(3): 2 20 202 2023 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 1 0 0 0 11 7 ;():.://././. 13 10 0 0 0 0 1
reval. 2023. reval. r re rev reva BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 11 7 ... 3 4 0 0 0 0 1
28. Gandhi 28. 2 28 28. 28. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 11 8 .,,,, 5 9 0 0 0 0 1
Stahl N, stahl S St Sta Stah BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 1 0 0 0 0 0 0 11 8 ,. 2 8 0 0 0 0 1
drivers of drivers d dr dri driv BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 11 8 . 1 9 0 0 0 0 1
Drug Discov. drug D Dr Dru Drug BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 11 8 .;():-.://./. 13 10 0 0 0 0 1
1038/ nrd46 1038/ 1 10 103 1038 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 1 0 0 0 11 8 /. 2 2 0 0 0 0 1
29. Xiang 29. 2 29 29. 29. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 11 8 .-,,,. 6 10 0 0 0 0 1
with autoimmune with w wi wit with BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 11 8 no 0 7 0 0 0 0 1
also have also a al als also BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 11 8 ,. 2 8 0 0 0 0 1
J Allergy j J J J J BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 1 0 0 0 0 0 0 0 11 8 .;():-. 7 8 0 0 0 0 1
e1. https:// e1. e e1 e1. e1. BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS CONTAINSDIGITS 0 0 0 0 0 0 0 0 11 8 .://././..... 13 9 0 0 0 0 1
30. Kolkhir 30. 3 30 30. 30. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 11 9 .,,,, 5 8 0 0 0 0 1
Schmetzer O, schmetzer S Sc Sch Schm BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 11 9 ,. 2 8 0 0 0 0 1
spontaneous urticaria: spontaneous s sp spo spon BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 11 9 : 1 7 0 0 0 0 1
what we what w wh wha what BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 11 9 .. 2 8 0 0 0 0 1
2017;139(6):1772-81. https:// 2017;139(6):1772-81. 2 20 201 2017 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 1 0 0 0 11 9 ;():-.://././. 14 10 0 0 0 0 1
jaci. 2016. jaci. j ja jac jaci BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 11 9 .... 4 4 0 0 0 0 1
31. Konstantinou 31. 3 31 31. 31. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 11 10 .,,,. 5 9 0 0 0 0 1
taskforce position taskforce t ta tas task BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 0 0 0 0 0 0 11 10 :- 2 8 0 0 0 0 1
mune urticaria mune m mu mun mune BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 11 10 - 1 8 0 0 0 0 1
tic criteria. tic t ti tic tic BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 11 10 ..;():-.://. 12 10 0 0 0 0 1
org/ 10. org/ o or org org/ BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 11 10 /./.. 5 4 0 0 0 0 1
32. Konstantinou 32. 3 32 32. 32. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 11 10 .,,, 4 8 0 0 0 0 1
I, Maurer i, I I, I, I, BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 11 10 ,.:- 4 8 0 0 0 0 1
standing complex standing s st sta stan BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 11 10 no 0 8 0 0 0 0 1
patient communication, patient p pa pat pati BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 11 10 ,, 2 8 0 0 0 0 1
future treatment. future f fu fut futu BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 11 10 .. 2 8 0 0 0 0 1
2023;11(1):94-106. https:// 2023;11(1):94-106. 2 20 202 2023 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 1 0 0 0 11 10 ;():-.://././.. 15 10 0 0 0 0 1
2022. 11. 2022. 2 20 202 2022 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 1 0 0 0 11 10 ... 3 2 0 0 0 0 1
33. Harris 33. 3 33 33. 33. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 11 11 .,,,.- 6 10 0 0 0 0 1
domized trial domized d do dom domi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 11 11 - 1 9 0 0 0 0 1
tory chronic tory t to tor tory BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 0 0 0 0 0 0 11 11 . 1 9 0 0 0 0 1
Immunol. 2016;138(6):1730-2. immunol. I Im Imm Immu BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 11 11 .;():-.://./. 13 9 0 0 0 0 1
1016/j. jaci. 1016/j. 1 10 101 1016 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS CONTAINSDIGITS 0 0 0 0 1 0 0 0 11 11 /..... 6 5 0 0 0 0 1

